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ABSTRACT 
 Neurodegenerative diseases are a large burden to the society. They are characterized 
by a loss of neuronal cells that affect the ability to perform daily activities, and are often 
caused by environmental or genetic factors. Therapeutics can treat clinical symptoms of 
chronic disease, but there is a need to additionally treat the underlying mechanisms leading to 
neuronal atrophy, such as mitochondrial dysfunction and inflammation. Efficacious treatment 
is very difficult due to the existence of several physiological hurdles, including the blood-
brain barrier, diseased neuron, and intracellular organelle. Targeted nano-carriers can 
enhance local bioavailability by targeting each of these hurdles. Polyanhydride nanoparticles 
(NPs) in particular are attractive nano-carriers for central nervous system delivery of 
therapeutics, and can easily be functionalized with targeting ligands to further improve 
delivery. 
The goal of the project detailed herein is to rationally design a functionalized 
polyanhydride NP drug delivery platform addressing all physiological hurdles of the 
neurovascular unit to combat neurodegeneration. First, functionalized and non-functionalized 
20:80 CPH:SA polyanhydride NPs were evaluated for the ability to cross the BBB in vitro. 
These NPs demonstrated promise in the ability to cross the BBB. Second, bulk-
functionalized 20:80 CPH:SA NPs were evaluated for the ability to be internalized by 
neurons and enhance protective capability of antioxidants against oxidative stress in vitro. It 
was found that the functionalized NPs demonstrated superior internalization by N27 neurons 
compared to non-functionalized NPs, and antioxidant-loaded NPs protected against hydrogen 
peroxide – induced oxidative stress. Collectively, these studies lay the foundation for further 
investigation of the functionalized NP platform for central nervous system drug delivery.
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CHAPTER 1: INTRODUCTION 
1.1 Neurodegenerative Diseases and CNS Drug Delivery 
Neurodegenerative disease comprises a complex set of pathologies affecting a large 
proportion of the population. The National Institute for Neurological Disorders and Stroke 
estimates that 50 million Americans each year suffer from one of over 600 neurological 
disorders [1]. In general, the disorders are associated with debilitation of physiological and 
cognitive function, and can result in inability to perform daily living activities [2–4]. Caring 
for these chronically disabled patients significantly burdens the families of the patient and the 
national healthcare system; the national cost of Parkinson’s disease (PD) care in the US was 
greater than $14.4 billion in 2010, and is expected to increase with the aging “Baby Boomer” 
population [5]. Both PD as well as other neurodegenerative conditions may be linked to a 
variety of environmental and genetic factors [6]. One of these factors is chemical exposure. 
Chemical exposure is a burden to the society, with as many as 3 million individuals being 
exposed each year worldwide, about 10% of which are fatal [7]. Fatality is often caused by 
what is known as the organophosphate toxicity phase that leads to status epilepticus, or 
seizures [8]. Even with survival, many other symptoms occur after the acute phase, and must 
be treated effectively to avoid progression of neuronal atrophy [8]. 
A common symptom that occurs in neurons soon after organophosphate exposure is 
oxidative stress, which progresses towards widespread cell death [9]. Rapid treatment of 
oxidative stress in neurons is therefore essential to prevent disease progression. Many drugs 
have been used to treat oxidative stress, but several complex physiological hurdles 
surrounding the brain make delivery of most therapeutics highly challenging [10]. 
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In order to improve drug delivery by improving half-life and providing sustained 
release, biocompatible platform technologies are typically used to encapsulate or chemically 
link a drug payload [11]. Additionally, many of these materials offer suitable chemistry for 
facile linkage of functional groups, or targeting ligands, to facilitate transport across multiple 
barriers associated with neural delivery [11,12]. Such simple linkages offer a versatile mix-
and-match capability, in that a functionalization used on one platform can often be replicated 
on another to exploit that platform’s physical properties. Polyanhydrides are a particularly 
attractive option for use as a central nervous system (CNS) therapeutic delivery platform, 
because of their proven sustained release in the brain and dose-sparing properties, and the 
feasibility of ligand functionalization onto polyanhydride copolymer chemistries [13–16]. 
For maximum efficacy, a drug delivery system must achieve a high local 
concentration of its payload near the organelle of action within the afflicted cell [17]. To do 
this, the device must (1) enable delivery across the blood-brain barrier (BBB) from the site of 
administration to the brain, (2) facilitate uptake by the afflicted neuronal cell, and (3) achieve 
localization at the desired organelle before releasing the payload. The vastly different 
biological, chemical, and physical conditions required for navigating each of these barriers 
present a complex, multiscale problem. To effectively target all of these barriers using 
targeting ligands, this work investigated a novel bulk functionalization method. With this 
method, the targeting ligand will remain part of the NP throughout degradation for effective 
multiscale targeting. The versatility of the polyanhydride NP platform also allows for 
functionalizing other ligands to the surface of the NPs (in addition to functionalizing in bulk) 
for significantly improved multiscale targeting. This thesis describes in vitro studies that 
have been accomplished to demonstrate the promise of this platform for CNS delivery. 
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1.2 Thesis Organization 
Chapter 2 provides a literature review of chemical exposure and chronic 
neurodegeneration pathology, as well as information on targeting strategies used for delivery 
across the BBB, to the diseased neurons, and to the mitochondria. Platform technologies that 
can facilitate delivery are also discussed. The mission of this project is to synthesize this 
information and develop and optimize a CNS polyanhydride delivery platform for treatment 
of symptoms associated with chemical exposure, chiefly oxidative stress. 
 Chapter 3 expands upon the polyanhydride NP platform by investigating the ability of 
NPs based on 1,6-bis(p-carboxyphenoxy)hexane and sebacic acid (i.e., 20:80 CPH:SA) to be 
transported across the BBB in vitro. Chapter 4 then evaluates the potential for 20:80 CPH:SA 
NPs functionalized with the BBB and mitochondrial targeting ligand triphenylphosphonium 
(TPP) to be internalized by neurons and co-localize to mitochondria. In addition, the 
hypothesis of enhanced protection of these NPs (encapsulating the antioxidant Mito-
apocynin) over a soluble drug dose is tested. Chapter 5 summarizes the conclusions reached 
and suggests routes for future work using a cascading multiscale targeting NP platform based 
on the one tested in Chapters 3 and 4. 
 
1.3 Acknowledgments 
 Information in this chapter was taken and modified from a review paper to be 
submitted to the Biomedical Materials Journal, July 31 2017, titled “Cascading Multiscale 
Nanodelivery Devices for CNS Delivery of Regenerative Therapeutics”, as detailed in 
Chapter 2 below. 
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CHAPTER 2: CASCADING MULTISCALE NANODELIVERY DEVICES TO 
COMBAT NEURODEGENERATIVE DISEASE 
 
Modified from a review paper to be submitted to the Biomedical Materials Journal, July 31 
2017, titled “Cascading Multiscale Nanodelivery Devices for CNS Delivery of Regenerative 
Therapeutics”. 
 
Benjamin Schlichtmann1,a, Adam Mullis1,a, Rebecca Cademartiri1, Balaji Narasimhan1, Surya 
Mallapragada1,* 
 
1 Department of Chemical and Biological Engineering, Iowa State University, Ames, IA 
50010 
a These authors contributed equally to this work 
* To whom correspondence should be addressed 
 
2.1 Abstract 
Neurodegeneration is a disabling set of conditions and contributes to around 30% of 
neurological-related deaths each year [1]. Toxicity from chemical exposure to toxic 
organophosphates such as nerve agents or pesticides contributes to a large portion of 
neurodegenerative disease, with as many as 3,000,000 exposure cases every year [2]. While a 
number of therapeutics have been explored for treatment resulting from chemical exposure, 
clinical translation has been limited. Improvements with the delivery of therapeutics have the 
potential to enhance the standard of treatment by increasing local drug concentration at the 
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pathologically-relevant cells and organelles. However, achieving efficient drug delivery 
requires the ability to target and overcome three physiological hurdles, including the blood-
brain barrier (BBB), the diseased neuron, and the intracellular organelle. These barriers 
significantly reduce drug bioavailability and overall efficacy, presenting a complex, 
multiscale problem. Multiscale drug delivery systems could address these issues by 
incorporating targeting mechanisms for each of the three associated barriers at 
physiologically relevant times. A large body of work has been performed to address 
individual aspects of this problem, but few studies address the reality that functionalizations 
intended to overcome one barrier may hinder or be hindered by the local environment 
elsewhere along the pathway [3–8]. This review first seeks to provide a background on 
neurodegenerative disease and therapeutics used to treat it. Delivery platforms for treatment 
of neurodegenerative disease will additionally be evaluated. Finally, recent literature that 
addresses the properties needed to target the complex hurdles will be discussed. Synthesizing 
this information will enable the rational design of multiscale delivery systems for 
neurodegenerative disease.  
 
2.2 Introduction to Neurodegenerative Disease and Chemical Exposure 
Neurodegenerative disease is a complex set of disorders that affect a significant 
proportion of the population [9]. In general, they are associated with debilitation of 
physiological and cognitive function, and can result in inability to perform daily living 
activities [10–12]. Caring for these chronically disabled patients significantly burdens the 
families of the patient and the national healthcare system; the national cost of Parkinson’s 
disease (PD) care in the US was greater than $14.4 billion in 2010, and is expected to 
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increase even further [13]. These diseases may be linked to a variety of environmental and 
genetic factors, however many of the most prevalent diseases have similar pathology [14]. 
Oxidative stress, in particular from exposure to dangerous toxins, for example, is often a 
precursor for chronic neurodegeneration if left untreated [15]. 
 
2.2.1 Acute symptoms of chemical exposure 
Upon exposure to nerve agents, acute nerve agent toxicity leads to disruption of 
proper neuronal synaptic function and mitochondrial dysfunction [15]. In the acute toxicity 
period, the toxic chemicals interfere with central nervous system (CNS) synaptic function by 
binding to acetylcholinesterase, which normally cleaves and deactivates excess acetylcholine 
[16]. Excess acetylcholine leads to the persistent activation of ionotropic ligand-gated 
channels that allow an abnormally high concentration of calcium into the cell and can 
drastically change expression of enzymes, causing cellular dysfunction [17,18]. Status 
epilepticus (SE), or seizures, is often the first symptom of nerve agent exposure and is due to 
a constant firing of action potentials resulting from persistent activation of the nicotinic 
channels. 
In addition, neuron-neuron synaptic function in CNS is affected by increased levels of 
glutamate, the most ubiquitous neurotransmitter in the CNS [18,19]. The resulting high 
intracellular calcium concentration increases mitochondrial membrane permeability and leads 
to production of reactive oxygen and nitrogen species (ROS and RNS, respectively) along 
with overall mitochondrial dysfunction [18]. High levels of superoxide radicals lead to 
increased expression of the nicotinamide adenine dinucleotide phosphate-oxidase (NOX-2) 
enzyme which produces extracellular ROS and RNS that spreads throughout the brain 
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parenchyma [17,20]. Normally, the mitochondria induces production of antioxidants that can 
combat the build-up of ROS and RNS [15], but abnormally high levels lead to neuronal 
atrophy [21]. Associated increased levels of glial cell activation and an inflammatory 
response by microglial cells in the neurovascular unit (NVU) also appear after insult [22]. It 
is important to treat oxidative stress quickly, because ensuing neuronal atrophy causes 
irreversible injury to the brain [22]. 
 
2.2.2 Chronic disease progression 
Nitric oxide (NO) plays a major role in oxidative stress – induced neurodegeneration 
[22,23]. NO induces N-methyl-D-aspartate (NMDA) receptor overexpression through 
interference with glutamate, leading to oxidative stress in the affected cells [22]. 
Overexpression of NO to toxic levels is apparent in both PD and Alzheimer’s disease (AD) 
[22]. In addition, neuroinflammation of the brain past normal levels will lead to overall loss 
of function. Specifically, increased expression of isoform NO synthase (iNOS) is commonly 
associated with neurodegeneration, and serves as a marker for evaluating disease state 
[22,23]. 
Many cases of nerve agent exposure will eventually lead to chronic symptoms [18]. 
The aggregation of misfolded or mutated proteins (also called Lewy bodies (LB)) has been 
causally linked to chronic disease progression [24–26]. These aggregated deposits inhibit 
proper synaptic function. AD, which affects pyramidal neurons in the hippocampus, can 
often be characterized by the aggregation of amyloid-beta (Aβ) and tau protein [27–31]. 
Under normal function, Aβ proteins contribute to proper synaptic function in the CNS, but in 
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AD, overexpression of this protein leads to significantly inhibited synaptic function [32]. The 
increase in Aβ expression also leads to lipid membrane peroxidation [22]. 
In contrast to AD, PD affects dopaminergic neurons, which exist primarily in the 
substantia nigra and striatal cortex [24,33,34]. One of the hallmarks of PD is the development 
of LBs, which are an aggregation of proteins resulting from the inability to degrade 
misfolded proteins through the polyubiquitination process in the cell [24]. The build-up of α-
synuclein protein, specifically from Leucine-rich repeat kinase 2 (LRRK2) mutations, in the 
extracellular matrix is one of the most common LB proteinopathies for PD, as well as that of 
ubiquitin [24,33,35,36]. Like Aβ, the α-synuclein protein is beneficial at normal levels for 
protecting degeneration of dopaminergic neurons but overexpression of the protein leads to 
neuronal toxicity [37]. As a result, a prolonged inflammatory response and NO production in 
glial cells that interferes with normal cellular function leads to cell atrophy [22].  
 
2.2.3 Therapeutics for chemical exposure and downstream pathologies 
There are four primary stages associated with chemical exposure from toxic 
organophosphates, including organophosphate toxicity, cholinergic excitotoxicity, secondary 
neuronal damage, and chronic disease progression [18]. An excellent review details 
therapeutics that have been used to protect against each of these stages resulting from 
exposure [18]. The following section discusses drugs used to treat each of these stages. 
Anti-cholinergic drugs for treatment of organophosphate toxicity, occurring just a few 
minutes after exposure, must be administered rapidly and therefore are commonly 
administered in a bolus dose [38]. Atropine is an anticholinergic drug commonly used to 
alleviate symptoms, like SE, occurring in this phase [18,39]. Benactyzine and scopolamine 
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are also used to prevent the over-activation of acetylcholine that occurs during 
organophosphate toxicity [18,39]. When designing a platform for treatment of chemical 
exposure, incorporation of an anticholinergic drug must be considered. 
Cholinergic excitotoxicity occurs within hours after exposure, immediately following 
organophosphate toxicity [18]. Common symptoms of this phase include inflammatory 
reaction and excessive calcium influx into neurons, severely damaging the cell [18]. 
Antiglutamatergic drugs like caramiphen have been used to reduce symptoms of 
excitotoxicity [39]. Benzodiazepines, which increase the activity of GABA (an inhibitory 
neurotransmitter) in the brain, have also been used as treatment for this stage [18]. 
Oxidative stress typically occurs shortly after the end of the cholinergic excitotoxicity 
phase when the secondary neuronal toxicity phase begins. The onset of this stage occurs 
hours to days after exposure [40]. Protection against oxidative stress is imperative for 
preventing neuronal atrophy and progression of disease. Vitamin E, N-tert-butyl-α-
phenylnitrone (PBN), MitoQ, and apocynin are all examples of antioxidants that have been 
investigated [18,41]. Other enzymatic (superoxide dismutase) and non-enzymatic (vitamin C 
and coenzyme Q10) antioxidants have also been used to treat oxidative stress [42]. 
Apocynin combats oxidative stress by inhibiting expression of NOX-2, reducing the 
rate of ROS and RNS production; to be effective, it must localize to the mitochondria [43–
46]. The mitochondrial targeting lipophilic and cationic molecule triphenylphosphonium 
(TPP) has therefore been conjugated to the drug to improve targeting and efficacy [23]. TPP 
enhances adsorptive-mediated cellular internalization through electrostatic interactions with 
the negative neuronal membrane and the even more negative mitochondrial membrane 
[23,43,47–54]. A recent study found that a two carbon chain TPP conjugated to apocynin 
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Mito-apocynin C2 (Mito-Apo C2) is up to 100 times more effective than apocynin, and has 
protected against several oxidative stress and inflammatory markers in a soluble dose in vitro 
and in vivo [23]. A separate in vivo study with Mito-Apo C11 has shown reduction of the 
oxidative stress-related marker 4-HNE in the substantia nigra after treatment [55]. 
Alternatively, the mitochondrially-targeted antioxidant MitoQuinone (MitoQ) has also shown 
the ability to treat oxidative stress in vivo [56–58]. MitoQ has even been approved for human 
use [59]. As elucidated by the above examples, mitochondrial targeting is an attractive 
strategy to use for antioxidants [42]. 
To treat chronic symptoms of neurodegeneration, the drug saracatinib has been used. 
In contrast to antioxidants, this therapeutic acts by inhibiting src family kinases (SFKs) [60]. 
These SFKs are upregulated by prion protein, the activation of which is initiated by the 
binding of Aβ [61]. SFKs modulate very important cell surface receptors in neurons, the 
over-expression of which can lead to significant neuronal toxicity [62]. Clinical trials of 
saracatinib have shown that this drug can reach the CNS and protect against 
neurodegeneration [60]. 
Memantine is also a neuroprotective drug for combating neurodegenerative disease. It 
prevents further degeneration by acting as an NMDA receptor antagonist, therefore limiting 
excessive ion inflow into neurons [41]. In a combination study with the antioxidants vitamin 
E and PBN, memantine has successfully protected against ROS and RNS through this 
mechanism [41]. However, it may not be suited for clinical use due to limited efficacy 
observed in late stages of AD-based neurodegenerative mouse models [63]. 
Alternatively, some therapeutics act directly on the aggregated protein deposits that 
often occur in diseases such as AD or PD. One example evaluated the effect of transcription 
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factor EB (TFEB) to reduce the amount of aggregated α-synuclein [26]. The study found that 
TFEB effectively reduced the aggregation of α-synuclein by promoting autophagic clearance 
[26]. Such a treatment may have promising implications for treatment of chronic symptoms 
associated with neurodegenerative diseases like PD. 
In addition to the listed therapeutics, many other drugs have been incorporated at each 
level of exposure, from acute to chronic [18]. However, an issue existing with delivery of 
these therapeutics is achieving specificity (leading to low bioavailability) as well as low 
therapeutic half-life. These issues can be overcome by (1) using a nanoscale platform to 
deliver the drug and protect it from degradation (section 2.3), and (2) functionalizing this 
platform with targeting ligands to further enhance local bioavailability (section 2.4). 
 
2.3 CNS Delivery Platforms 
Drug delivery platforms can protect the drug from systemic degradation, provide 
sustained release, targeting and dose-sparing effects, and overall improve drug efficacy [64]. 
A number of nanoscale delivery platforms address several challenges associated with neural 
delivery, and will be discussed below. The most well-studied CNS delivery platforms include 
micelles, liposomes, dendrimers and nanoparticles (NPs) [65]. 
 
2.3.1 Micelles 
Micelles have been used in CNS delivery applications. Having amphiphilic properties 
with a hydrophobic core, they can be used to carry hydrophobic drugs to improve 
localization [65]. In fact, a study found that micelles can improve the therapeutic effect of 
antioxidants [66]. However, due to long circulation time, micelles are often unstable in vivo 
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and therefore display lower improvements in drug efficacy, when not conjugated to stability-
enhancing molecules like Poly(ethylene glycol) (PEG) [67]. 
 
2.3.2 Liposomes 
 Liposomes also have several favorable characteristics for CNS multiscale delivery. 
They have great biocompatibility, ability to encapsulate multiple types of therapeutics, and 
versatility in the ability to functionalize with targeting ligands [65]. Recent work has shown 
the ability of liposomes coated with PEG to improve treatment for symptoms associated with 
AD [68,69]. However, like micelles, liposomes are typically unstable in vivo and cannot 
easily provide sustained release for therapeutics without modification using molecules like 
PEG [65]. 
 
2.3.3 Dendrimers 
Dendrimers are a popular nanoscale delivery option for CNS therapeutic delivery. 
First, the structures of dendrimers contain many functional groups that allow for the ability to 
conjugate therapeutics and significantly improve bioavailability, which makes them very 
versatile [49,70]. Additionally, therapeutics conjugated to dendrimers have demonstrated 
enhanced circulation times [49]. Dendrimers have been conjugated to the mitochondrial 
targeting ligand TPP to investigate potential improvements in mitochondrial co-localization 
[49]. Importantly, dendrimers have also demonstrated great biocompatibility [48]. However, 
the versatility of this platform is sacrificed by the fact that drugs for treatment of CNS 
disease are conjugated onto the surface functional groups [71]; this limits the predictability of 
release timescale that can be seen with NPs. 
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2.3.4 Nanoparticles 
2.3.4.1 Poly(esters) 
Poly(esters) are a very well-studied therapeutic delivery vehicle, with great support 
by the FDA. Furthermore, poly(lactic-co-glycolic acid) (PLGA)-based NPs are an attractive 
option for CNS therapeutic delivery studies [32,50,72–84]. However, a disadvantage of this 
nanoscale delivery platform is its bulk-eroding properties [85]. By allowing water penetration 
at a rate faster than polymer bond cleavage, PLGA NPs expose the therapeutic to 
surrounding fluids prior to presentation at the targeted site [85]; this can lead to significant 
therapeutic degradation. In addition, the complex release profile of these NPs makes it very 
difficult to control the therapeutic release rate when designing an optimal delivery platform 
[86]. These issues are further compounded when sustained therapeutic release of drug is 
required. Nevertheless, the proven safety and relative ease for conjugation of PLGA makes it 
an attractive option for overcoming the challenging hurdles associated with CNS delivery 
[87].  
 
2.3.4.2 Polyanhydrides 
Polyanhydrides demonstrate many advantages over competing drug delivery devices 
in the context of CNS delivery [88]. A significant advantage they hold over popular bulk-
eroding nanoscale drug delivery platforms like PLGA is their surface-erosion mechanism. 
This mechanism occurs based on two main structural features. First, diacid monomers that 
form the backbone of polyanhydrides are relatively hydrophobic, and therefore reject water 
from penetrating into the bulk of NPs made from this polymer [89]. Second, the anhydride 
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bonds that link the monomers are hydrolytically labile [89]. These features lead to the 
cleavage of anhydride bonds faster than water diffusion into the bulk, or surface erosion [89]. 
Moreover, surface erosion of drug-encapsulated NPs allows for more predictable drug release 
rates, governed by near zero-order therapeutic release kinetics [88,90]. 
Additionally, polyanhydride copolymer chemistries are easily tailorable, which has 
several advantages. The ability to control chemistries with different hydrophobic and 
degradative properties allows for precise control of the timescale of release, ranging from 
days to weeks to months [88,91]. This versatility arises due to differences in monomer 
hydrophobicity used for the NP formulation [92]. Versatility in polyanhydride chemistry is 
also beneficial when considering therapeutic thermodynamic compatibility requirements. For 
example, proteins are amphiphilic molecules; by altering polyanhydride chemistry to be more 
amphiphilic using 1,8,-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), a novel 
polyanhydride developed by the Narasimhan lab, the stability of proteins encapsulated in 
these NPs can be significantly improved [93]. 
The surface-eroding properties of polyanhydrides are also advantageous over bulk-
eroding NPs because they protect the therapeutic from exposure to, and degradation in, 
surrounding fluid [94]. Reduced drug degradation and premature release from NPs may lead 
to increased local bioavailability, improving drug pharmacodynamics [95]. In addition to this 
enhanced therapeutic protection, polyanhydride degradation products (dicarboxylic acids) do 
not significantly alter physiological pH, which can otherwise lead to significant therapeutic 
degradation [89,96]. 
Polyanhydrides have shown great biocompatibility in numerous studies [88,96,97]. 
This is attributed to the relatively low inflammatory response [88], as well as the ease with 
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which both aromatic and aliphatic monomers are removed from the body after degradation 
[89,92,96]. As an FDA-approved example demonstrating the biocompatibility of 
polyanhydrides, the carmustine-encapsulated wafer for the treatment of brain cancer shows 
the benefit of sustained release provided by a surface-eroding polyanhydride formulation of 
20 mol% carboxyphenoxypropane (CPP) and 80 mol% SA [98]. 
The 20:80 CPH:SA chemistry has many advantages that suggest its use as a delivery 
platform for improving treatment of oxidative stress. 20:80 CPH:SA NPs release payload in 
7-10 days [99], a faster timescale that can effectively treat oxidative stress from nerve agent 
exposure [18]. Superior uptake of 20:80 CPH:SA NPs by monocytes [100] and macrophages 
[101] suggests this formulation could utilize cell-mediated transcytosis mechanisms 
(discussed below) for crossing the BBB, even without functionalization. The binding of 
several serum proteins that have affinity for BBB-expressed receptors, including 
apolipoprotein E, may further enhance localization efficacy [102–106]. Overall, there may be 
several mechanisms at play with this formulation where improved cellular internalization 
could be observed, which make it a promising platform for CNS delivery. 
It is imperative, when designing a nano-carrier, to consider thermodynamic 
compatibility between the drug and the polymer. This compatibility may be affected by the 
copolymer’s microstructure [99]. For example, microphase separation occurs in 20:80 or 
80:20 CPH:SA copolymers, but not at 50:50, based on resulting block vs. random monomer 
organization [99]. Encapsulated therapeutics will often prefer to localize to one of the 
microphases and then be released while that microphase degrades. Release profiles of Mito-
Apo C2-encapsulated 20:80 CPH:SA polyanhydride NPs, a promising nanoscale platform for 
CNS delivery, have shown compatibility with the SA microphase [40], which degrades faster 
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than the CPH microphase. This rapid timescale of drug release with this specific drug and 
chemistry combination is favorable for treatment of oxidative stress-induced toxicity 
following acute toxic exposure. In addition to the other advantages of polyanhydrides listed 
above, this platform is a lead candidate for CNS delivery strategies. 
 
2.4 CNS Targeting Strategies 
Designing a nanoscale delivery platform that can more effectively cross the complex 
hurdles in CNS drug delivery (Fig. 2.1) using targeting ligands is essential. Numerous studies 
and reviews have investigated strategies for targeting one of these hurdles. A summary of 
several of these solutions can be found in Table 2.1. However, few studies have looked at 
targeting two and even fewer looked at targeting all three with the same platform. The 
following section discusses targeting strategies that have been used at each scale, with the 
goal of being able to rationally design a CNS delivery platform by synthesizing these 
strategies to optimize a delivery platform. 
 
2.4.1 Blood-brain barrier 
The use of targeting ligands to improve the targeting capability of the platform at 
each level of CNS delivery is imperative for good drug pharmacodynamics. The first hurdle 
for CNS therapeutics is often the BBB. Parenterally, orally or intravenously administered 
therapeutics intended for CNS delivery must cross the BBB from the circulation, and to do 
so, cross BBB endothelial cells. These cells reject transport of most small molecules because 
of strong tight junctions that are influenced by interaction with glial cells in the NVU and 
leave little space for paracellular transport [64,107–109]. Extracellular proteins on these 
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endothelial cells, called efflux pumps, reject small molecule transport, further complicating 
delivery [64,110]. 
There are three primary ways by which targeting ligands can improve BBB targeting. 
These include receptor-, adsorptive-, and cell- mediated transcytosis [64,110]. These 
mechanisms utilize compositional features of the BBB, such as the high concentration of a 
particular cell-surface receptor, to improve localization. In addition, the diseased state often 
has characteristics that targeting ligands can exploit. This may include targeting immune 
cells during the inflammatory response to facilitate passage across the BBB through these 
cells as they travel to the site of injury; these cells can be targeted and used to deliver 
therapeutics across the BBB. Weakened BBB tight junctions in the diseased state may also 
enhance the paracellular transport rate [110]. In the context of nerve agent exposure, 
however, these symptoms often do not become severe until chronic neurodegeneration, and 
therefore may be more difficult to utilize for drug delivery [109]. Nevertheless, the following 
sections detail methods for targeting using each of the three mechanisms. 
 
2.4.1.1 Receptor-mediated strategies 
Receptor-mediated transcytosis mechanisms for therapeutic delivery platforms 
exploit the endocytic mechanisms of cell-surface receptors existing at the BBB using the 
appropriate receptor-targeted ligands. Targeting in such a way minimizes therapeutic 
circulation time. The sugars di-mannose, galactose and glycolic acid have been employed to 
target lectin receptors [111]. Additionally, receptors for folic acid (FA) and des-octanoyl 
ghrelin exist in large quantities on the surface of BBB endothelial cells and as such have been 
incorporated in several drug delivery studies [40,107,112–114]. 
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Some receptor-mediated strategies utilize proteins that have an affinity for BBB cell 
surface receptors. Some protein-incorporated strategies utilize apolipoproteins A, B, and E, 
a2-macroglobulin, and angiopep-2 for targeting the low-density lipoprotein receptor [102–
104,115,116]. The glycoprotein 330/megalin receptor can be targeted using apolipoprotein J, 
and scavenger receptor class A by fucoidin [115]. Interleukin 13 (IL-13) protein can be used 
target the IL-13 receptor on the BBB [117,118]. Additionally, Intracellular adhesion 
molecule-1 (ICAM-1) is a receptor expressed on the BBB and can be targeted to improve 
localization [6,8,115]. 
Targeting the transferrin receptor is a common BBB targeting strategy. One study 
found specific CNS localization compared to other organs after conjugating an anti-mouse 
transferrin receptor monoclonal antibody to a chitosan nano-sphere formulation coated with 
PEG [119]. A review details that both transferrin and insulin receptors have been targeted 
using a particular monoclonal antibody, 83-14 MAb [120]. The transferrin and lactoferrin 
glycoproteins, and a transferrin binding antibody OX-26 have all been used in BBB models 
[64,121,122]. The OX26 monoclonal antibody has also been used to target the transferrin 
receptor on the BBB in vitro [123]. Other targeting strategies incorporated targeting ligands 
for both the transferrin receptor (for BBB targeting) as well as for aggregated protein 
deposits (for neuronal targeting) [68,124–127]. 
Polymeric or surfactant coatings can also increase localization at the BBB level. 
Many of these methods demonstrate indirect targeting through the adsorption of serum 
proteins that will then target a receptor on the BBB. Surfactants Tween-20 and Tween-80 
have shown the ability to do so by absorbing serum-rich apolipoproteins that target the BBB 
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[79,102]. Alternatively, polyethylene glycol (PEG) is used in many formulations 
incorporating targeting mechanisms to prolong circulation half-life [64,128,129]. 
 
2.4.1.2 Adsorptive-mediated strategies 
Adsorptive mediated strategies target the BBB by affinity with and adsorption to the 
lipid membrane. Several peptides have demonstrated the ability to improve targeting using 
this mechanism [130]. The streptavidin-binding peptide (SBP), fibronectin-binding peptide 
(FBP), multiple antigenic peptides (MAPs), trans-activating transcriptional activator (TAT), 
transportan, insulin, pAntp, rabies virus glycoprotein, angiopep, penetratin, SynB1, and 
SynB3 have all been used to improve therapeutic CNS delivery [64,82,83,131,132]. TAT 
peptide is a well-researched peptide for cerebral delivery for its ability to enhance BBB 
passage [131]. BBB shuttle peptides increase therapeutic delivery across the BBB by 
transcytosis through endocytic vesicles, and are discussed in a recent review [109]. 
The cationic and lipophilic ligand TPP is a promising molecule for promoting 
adsorptive-mediated transcytosis at the BBB. A recently submitted patent by Dhar et al. 
shows that a TPP-functionalized NP has brain-specific bioavailability compared to the same 
NP platform without functionalization [133]. This work evaluated localization using a 
porcine model [133]. In this model, drug efficacy and localization was evaluated after 
traumatic brain injury, with similar downstream pathologies to chemical exposure [133]. 
 
2.4.1.3 Cell-mediated strategies 
After brain injury, immune cells are recruited into the brain as part of the 
inflammatory response. These immune cells can internalize the nanoscale delivery platform 
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as a “Trojan horse” strategy where these cells then guide the platform into the CNS and 
release them after crossing the BBB. A recent review details strategies that have investigated 
this mechanism [134]. A major example in this field involves targeting the folate receptor on 
immune cells by conjugating FA to NPs to combat human immunodeficiency virus (HIV) 
[135–139]. 
In one study, conjugation of FA to poloxamer 407, in an antiretroviral NP 
formulation, improved uptake by mononuclear phagocytes in vitro, reduced the amount of 
HIV-1 gag expression (a marker for HIV pathogenesis) in the brain, and demonstrated 
enhanced brain uptake in vivo  in mice compared to non-functionalized NPs [135]. A later 
study by the same group tested lead candidates and found enhanced uptake and prolonged 
retention in vitro and in vivo, as well as increased protection in vitro [138]. Similar results 
were obtained with these lead candidates in a primate model [136]. The group further 
investigated FA for combating HIV-1p24 antigen [137]. Dose-sparing, in addition to 
increased overall pharmacokinetics and pharmacodynamics, were observed when coating the 
lead formulation with FA, specifically by increasing uptake by the folate receptor β [137]. 
Importantly, dose-sparing was observed in this platform in an in vivo mouse model [139]. 
Overall, cell-mediated transcytosis offers a unique and effective strategy for targeting the 
BBB, when choosing an appropriate targeting ligand. 
 
2.4.1.4 Other strategies 
Alternatively, BBB tight junctions can be disrupted to promote paracellular transport. 
Granulocyte macrophage colony-stimulating factor (GM-CSF) enhanced BBB transport by 
activation of monocytes that occurred due to the activation of several expression pathways; 
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this was coupled with a disruption of BBB tight junctions [140]. Ultrasound has also been 
used to disrupt the BBB and allow therapeutic delivery [141]. However, these methods are 
risky because they damage the normal protective function of the BBB that then exposes the 
brain to other potential toxins. 
 
2.4.1.5 Obstacles for BBB targeting 
Issues with ligand specificity are important to consider for platform design. For 
example, receptor-mediated targeting ligands that improve transcytosis at the BBB often 
have receptors that are ubiquitous throughout the body [6]. Adsorptive-mediated targeting 
may experience similar issues with specificity. Poor specificity often necessitates higher 
dosing and often leads to systemic toxicity. Therefore, the choice of the nanoscale delivery 
platform is important, to reduce the amount and frequency of doses and improve specificity. 
For degradable delivery platforms conjugated to a targeting ligand, incomplete 
purification may result in an excess of the targeting moiety in the surrounding fluid. It is 
possible that in this case, the targeting ligand may outcompete the platform for entry [138]. 
Purification of the platform from the free targeting ligand is important to avoid this 
possibility. In addition, retention of the targeting ligand throughout degradation of the 
biodegradable platform is important so that hurdles downstream of the BBB can also be 
effectively targeted. This requires careful design of the way the ligand is conjugated to the 
platform. For example, ligands conjugated onto the surface of the platform may not retain the 
ligand long enough to target these downstream hurdles, but ligands conjugated into the bulk 
may display longer retention and therefore more effectively target these hurdles. 
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2.4.2 Diseased neuron 
Once a delivery platform is inside the CNS after crossing the BBB, it must then 
localize to the diseased neuron. Several strategies exist for targeting the neuron, and will be 
discussed below. In some cases, these strategies may be disease-specific. 
In PD, mutations of the LRRK2 gene/receptor often lead to LB formation [142]. 
Studies have therefore targeted LBs to improve efficacy [31]. One example of such a 
targeting strategy is to target α-synuclein, the aggregation of which into LBs is often a 
symptom of PD [36]. Antibodies can be engineered to target these deposits, although it is 
important with these strategies to ensure specified delivery of the therapeutic to only diseased 
neurons [31]. 
Likewise, the formation of Aβ deposits that disrupt synaptic communication is 
common in AD. Several targeting strategies have therefore used ligands to target these 
deposits. For example, a study incorporated an anti-Aβ peptide antibody along with an anti-
transferrin receptor monoclonal antibody, on a polyethylene glycol-modified liposomal 
platform to improve delivery [124]. There was an interplay where the conjugation method for 
each antibody affected cellular uptake [124]. The same group later tested improvements in 
efficacy of a drug to treat Aβ aggregation in an AD model, again using dual functionalization 
of both anti-transferrin and anti-Aβ antibodies, but this time with PLGA NPs [78]. 
Curcumin can also increase targeting of Aβ deposits in AD. A multifunctional 
liposomal formulation incorporating curcumin to target neurons, with a transferrin antibody 
to target the BBB, showed enhanced localization at both levels [68]. Previous work by this 
group also showed improved targeting of liposomal-curcumin derivative formulations for Aβ 
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fibrils [125]. Yet another study focused on Aβ targeting by conjugating an Aβ-binding 
aptamer to curcumin-PLGA NPs and found success with this strategy [32]. 
Bispecific antibodies are a recent strategy that can potentially provide more 
efficacious therapeutic delivery. A study on such a platform found that there is an interplay 
between the dosing and antibody affinity for the targeted receptor, whereby low-affinity 
antibodies may be more effective in standard therapeutic dosing concentrations [126]. A 
different study evaluated these antibodies in a primate model, showing enhanced BBB 
passage and ability to target β-secretase, which is associated with Aβ deposition in AD, again 
showing lower affinity antibodies were more effective at localization [127]. While the use of 
antibodies as targeting ligands offers its own challenges in device design, including their size 
and complexity, antibody engineering can enable high specificity for the desired target and 
may be a promising option for CNS delivery [143]. 
Specific receptors on neurons have also been targeted to improve localization. The 
toll-like receptor 2 is commonly expressed on neurons in PD and AD, and therefore could be 
targeted to enhance drug delivery [30,36]. The gamma-aminobutyric acid (GABA) and 
dopamine receptors are specific to patients with Huntington’s disease and PD, respectively, 
and accordingly offer other targeting strategies for these diseases [144,145]. NMDA 
receptors may additionally be an effective neuronal receptor targeting strategy due to their 
ubiquitous nature on neurons [145,146]. A particular study used the NMDA receptor 1 
antibody, anti-NR1R, to improve drug pharmacokinetics [147]. An informative review 
details methods for synthesizing prodrug/antibody delivery platforms to target other 
neurotransmitter receptors, such as GABA, AMP and non-NMDA glutamate receptors [145]. 
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In addition to BBB targeting, FA has shown enhanced targeting at the neuronal level 
[40]. After challenging with an oxidative stress-inducing toxin, protection against oxidative 
stress in an FA-conjugated polyanhydride NP platform was improved compared to the non-
functionalized formulation [40]. Due to the ability to target multiple hurdles to CNS delivery, 
FA may be a promising option for conjugation to a delivery platform. 
There are also hurdles with neuronal delivery that must be considered during platform 
design. As with BBB receptor-mediated strategies, specificity of receptor-mediated targeting 
ligands can play a role in overall efficacy. In the example of NMDA receptor targeting 
methods, the diseased neuron may show an up-regulation of this receptor [145,146]. 
However, the NMDA receptor is a necessary component of all neuronal synapses, and may 
deliver drug to unintended neuron populations, in addition to the diseased neuron. Depending 
on the disease condition, protein deposits in the extracellular matrix may hinder efficient 
neuronal targeting and internalization [24–26]. 
 
2.4.3 Intracellular organelles 
The final hurdle to therapeutic delivery is targeting the payload to the desired 
organelle within the neuron. Therapeutic efficacy can be maximized by delivering the 
therapeutic payload to the organelle of action within the cell [3]. The scale of impact of 
organelle delivery is significantly smaller than the previous hurdles: whereas neuronal cell 
bodies can have a surface area on the order of tens to hundreds of square microns, the most 
relevant organelles for neurodegenerative disease, the mitochondria and nucleus, typically 
have surface areas of one to tens of square microns. For example, mitochondria are 
approximately 75-3.0 square microns in size, which limits the functional surface area for 
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interaction [148]. At this scale, physical and chemical properties play a larger influence on 
the success of targeting than seen at the other levels. Whereas crossing the BBB and neuron 
rely on protein-ligand or membrane interactions, size, morphology, and charge are primary 
determinants of intracellular accumulation. While a fair amount of work has been devoted to 
organelle-specific delivery in the CNS, the large majority has focused on other tissue types. 
Recent techniques for organelle-specific delivery are reviewed below, and their implications 
for treatment of neurodegenerative conditions are extrapolated. 
 
2.4.3.1 Endocytic pathway 
The primary concern in designing organelle-specific delivery devices is surviving the 
endocytic pathway. Nanoscale delivery platforms that exploit receptor-mediated endocytosis 
to navigate through the cell must be able to protect their payload from acidic hydrolysis and 
escape from endosomes and lysosomes. Several techniques for endosomal escape of delivery 
platforms have been developed (Fig. 2.2). Functionalization with certain classes of peptides, 
like cationic amphiphilic peptides, provide strong association with the endosomal membrane, 
which disrupts tension forces that stabilize the endosome resulting in pore formation [149]. 
Other approaches incorporate release of photoreactive molecules that degrade the endosomal 
membrane via production of ROS [149]. Alternatively, decoration with buffering agents such 
as quaternary and tertiary amines can cause an immense inflow of ions and water, which can 
rupture the endosome membrane due to osmotic pressure; this is commonly referred to as the 
“proton sponge effect” [149]. For more information, Varkouhi et al. have written an excellent 
review on ligands available for endosomal escape [149]. Once the delivery device has 
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escaped the endocytic pathway, other functionalizations or core properties of the platform 
can mediate transport to the therapeutic organelle of action. 
 
2.4.3.2 Mitochondria 
Mitochondrial dysfunction due to oxidative stress is a key pathogenetic pathway for 
many neurodegenerative diseases. Several therapeutics have been developed to halt or 
reverse this pathogenesis by interfering with production of superoxide groups. Mitochondria 
are bound by an inner and outer membrane and have a large transmembrane potential of 
approximately -180-200 mV [150]. Because of this membrane potential, charged molecules 
can efficiently localize at the surface of the mitochondria. However, the inner membrane is 
impervious to charged molecules, which precludes transport to the mitochondrial matrix 
[150]. These competing requirements are a central challenge for mitochondria-targeted 
delivery.  
Many technologies can be utilized to circumvent this mitochondrial trafficking 
challenge, the pathway for which is shown in Figure 2.2. An informative review details 
several methods for targeting the mitochondria [151]. The predominant technique is to 
conjugate a cationic molecule, such as TPP, to lipophilic platform materials [3,152]. This 
allows the carrier to be localized to the mitochondria through electrostatic attraction and 
subsequent permeation of the lipid bilayers by the delivery platform while the cation remains 
anchored outside the inner membrane [3]. Alternate strategies involve functionalization with 
ligands for mitochondrial receptors, like the translocator protein (TPSO) [153]. 
The cationic ligand TPP has demonstrated superior mitochondrial targeting 
capabilities [3,152]. The cationic properties of TPP may make the delivery platform act as a 
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proton sponge to escape the endosome inside the neuron. Afterwards, the negative 
mitochondrial membrane potential will attract the TPP-conjugated platform, where the 
therapeutic can then be released and internalized [3]. Because of the proven ability to also 
target and cross the BBB [133] as well as show enhanced neuronal internalization for better 
protection against oxidative stress using Mito-Apo both in vitro and in vivo [23,43,55], TPP 
is an excellent option for improving CNS delivery of antioxidants. 
It is challenging to determine, however, what qualifies as successful mitochondrial 
delivery. A large body of work in this field depicts accumulation of delivery devices at the 
mitochondria, but don’t conclusively show that the devices can cross the inner membrane for 
delivery. While some therapeutics may be able to enter the mitochondria passively given 
sufficient localization near the organelle, others may require a more active role from the 
delivery device. This must be carefully considered in platform design. 
 
2.4.3.3 Nucleus 
The nucleus can also be an important target for anti-neurodegenerative therapeutics. 
For example, RNA interference-inducing molecules could allow translational repression of 
problematic proteins, but must be delivered to the nucleus for processing via Drosha [154]. 
Alternative treatments include delivery of gene therapies to upregulate expression of 
regenerative neurotrophic factors in afflicted cells, which require nuclear localization for 
transcription and translation of the encoded proteins [155]. Additionally, nuclear delivery of 
genome editing technologies like CRISPR/Cas could allow development of new models of 
neurodegenerative disease, which could assist development of the next generation of 
neurodegenerative therapeutics [156]. By integrating nuclear delivery with neuronal delivery, 
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the off-target effects of this technology could potentially be mitigated, strengthening its 
potency as a transcription repression-based therapeutic [157]. 
Efficient nuclear delivery must also address trafficking issues downstream of 
endosomal/lysosomal escape, in this case to cross the nuclear envelope. Nuclear uptake is 
mediated by the nuclear pore complex (NPC), which can facilitate both passive and active 
transport of payloads [158]. Passive transport through the NPC has an effective diameter 
limit of approximately 9 nm, which means that most small molecule payloads can enter the 
nucleus without assistance from the carrier, given appropriate localization to the vicinity of 
the nuclear envelope [159]. Indeed, Shi et al. reported high nuclear localization of plasmid 
DNA in a DNA/ 25 kDa polyethylenimine polyplex despite a significant diversion of 
polymer into endosomal and lysosomal cell compartments [160]. Active transport, on the 
other hand, requires conjugation to a nuclear localization sequence (NLS) and can 
accommodate molecules up to 40-60 nm in diameter [158]. These NLSs are typically 
peptides of viral origin containing basic residues that bind NPCs for transport [3]. The most 
frequently used NLSs are SV40 peptide from simian virus 40 and TAT peptide from HIV-1 
[161–163].     
Transport of larger macromolecules into the nucleus poses a challenge, since many 
nano-carrier solutions are on the order of 50-200 nm in diameter. This limit can be increased 
by exploiting mitotic vulnerabilities in the nuclear membrane. However, this effect is modest, 
which still could exclude certain delivery platforms [164]. The non-proliferative nature of 
differentiated neurons further limits this technique’s applicability for neurodegenerative 
condition applications [165]. However, recent experiments have found that particle shape 
may be able to mitigate this size exclusion effect. Experiments by Chaturbedy et al. using 
31 
 
Fe3O4 NPs of different morphologies found that biconcave-shaped 220 nm-diameter NPs 
achieved relatively high levels of nuclear localization efficiency in U87 MG glial cells, 
especially when compared to cylindrical and spherical particles of similar hydrodynamic 
diameter [132]. This effect could greatly diversify the palette of delivery tools for nuclear 
delivery. These mechanisms for nuclear targeting are summarized in Figure 2.2.  
 
2.4.3.4 Obstacles for organelle targeting 
There are several challenges to organelle-specific delivery. Firstly, the therapeutic 
mechanism of action must be understood to identify appropriate organelle targets, which can 
be a significant challenge for newly discovered drugs or those with complex interactions. 
Additionally, pathological deficiencies associated with neurodegenerative disease can limit 
intracellular transport. For example, Zhao et al. identified deficiencies in lysosomal transport 
in a murine model of AD, which could have implications for delivery device trafficking and 
escape from the endocytic pathway [166]. 
A large challenge at this point lies in the relatively small body of work performed in 
organelle-specific delivery. Most research at this scale relies on in vitro characterization, with 
little validation in vivo [167]. To further compound this issue, a vast majority of publications 
that utilize a functionalized nano-delivery system fail to investigate the efficiency of 
organelle targeting of their system, and instead rely on qualitative assessments such as 
disease phenotype reversal [167]. Ultimately, there is a lack of investigation into which 
components of the delivery system result in organelle targeting, which hinders the ability to 
rationally design a nano-carrier for specific applications [167]. 
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Despite these shortcomings, the presented research has elucidated numerous 
mechanisms for improving localization of drug payloads at organelles of interest for 
neurodegenerative disease therapeutics. These functionalizations could potentially be 
combined with those highlighted in sections 2.3.1 and 2.3.2 to allow delivery devices to cross 
the BBB, and also effectively target the neuron and organelle. Regardless, both during and 
after the design of a platform, the method of administration must also be considered. 
 
2.4.4 Delivery route 
The delivery route also plays a significant role in drug efficacy for CNS delivery. The 
most common methods are intravenous (IV), intranasal (IN), and oral administration. 
Stereotaxy has even been used for treatment of brain cancer using biodegradable drug 
delivery materials, but is a very invasive procedure [98]. 
IN delivery is advantageous over other routes in that therapeutics delivered in this 
manner will follow a more direct route to the brain [168]. Instead of having to pass the BBB 
from the circulation, the therapeutic must instead pass through the olfactory and/or trigeminal 
nerve epithelial layers [130]. In addition, the comparatively slower mucociliary clearance 
rate of molecules at the nose-brain barrier (NBB) compared to circulatory clearance at the 
BBB may allow for greater uptake into these nerve epithelial layers [72].  
There are, however, challenges with IN delivery. Achieving deposition on the 
olfactory region for proper administration of the therapeutic is very difficult [72,168]. 
Previous work has found that administration and plume angles of the nasal spray play a 
particularly relevant role in achieving optimal olfactory uptake, with 30° administration 
angles and <30° plume angles being most effective in these studies [169]. Therefore, IN 
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delivery may be a difficult procedure to replicate reliably when testing the efficacy of the 
delivery platform, compared to other targeting strategies. 
In addition to difficulty in administration, platform efficacy may suffer without 
effective targeting ligands due to mucociliary clearance [72]. Chitosan [73,130] and solanum 
tuberosum lectin [72] are examples of NBB targeting ligands to avoid this issue. The TAT 
peptide is another ligand that can improve delivery across the NBB [76]. If the administration 
is performed reliably and an appropriate NBB-targeting ligand is incorporated onto the 
delivery platform, this method could be very effective at achieving great local drug 
bioavailability in the brain. 
Another route that can be used for CNS delivery is oral administration. The biggest 
advantage of the oral delivery route is that it is minimally invasive and patient compliant 
[79]. However, therapeutics administered in this fashion will take a very long time to reach 
the CNS because they will go through the metabolic process. This involves passing through 
the stomach, which has an extremely acidic pH that could lead to therapeutic degradation 
[170]. Once reaching the circulatory system (often through the intestinal track), these 
therapeutics must then find their way to the BBB. 
IV administration directly into the circulatory system, therefore bypassing some issue 
encountered with oral delivery, is another option. Therapeutics administered in this way must 
localize to and cross the BBB, like with oral delivery [171]. This route is much more reliable 
than IN delivery because of less specific administration parameters [171]. However, because 
IV injection requires skin penetration using a needle, it is significantly more invasive and 
may lead to poorer patient compliance compared to the other methods, particularly where 
repeat administrations are necessary [171]. Overall, the decision on delivery route is 
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important and could dictate or be dictated by the choice in targeting ligand and/or delivery 
platform, based on the hurdles encountered by that route. 
 
2.5 Conclusions 
Multiscale design strategies as outlined in this review offer the potential to maximize 
clinical translatability of nanoscale delivery platform technologies for therapeutic delivery in 
neurodegenerative disease. Polyanhydride NPs are an excellent platform choice, with 
tailorable release timescales, sustained therapeutic release, dose-sparing, superior phagocytic 
uptake, excellent biocompatibility, and versatility in the ability to conjugate targeting ligands. 
In addition, the targeting ligands FA and TPP are promising for the ability to target multiple 
of the physiological hurdles and as such are reasonable choices for conjugating to a 
polyanhydride NP platform. Overall, rational design of a platform incorporating these 
strategies could have tremendous implications for treatment of neurodegenerative disease, 
and requires testing at each scale in vitro. 
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2.8 Tables and Figures 
 
Figure 2.1. Organelle-specific delivery to neurons is a multiscale problem. To cross the 
BBB, and target the neuron and organelles within the neuron, a multifunctionalized delivery 
device must be used. Individual functionalizations can potentially cause off-target 
localization, so a cascading system of functionalizations with sheddable linkers is desired to 
maximize targeting efficiency. Modified from Chen et al, Li et al. [64,172]. 
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Figure 2.2. Organelle targeting mechanisms for neurodegenerative therapeutic delivery. 
Endosomal escape downstream of internalization is necessary for cytosolic trafficking to 
targeted organelles.  
 Table 2.1. General characteristics of functionalizations for multiscale delivery. 
Physiological 
Hurdle 
Mechanism 
General 
characteristics 
Examples Pros Cons References 
Blood Brain 
Barrier 
 
Receptor-
mediated 
endocytosis 
Carbohydrate 
FA, Mannose, 
Galactose 
high 
expression 
of receptors, 
stable 
limited 
selectivity 
[40,107,111–114] 
Protein 
apolipoprotein, 
fucoidin, IL-13, 
angiopep-2, 
rabies virus 
glycoprotein 
highly 
specific 
limited 
stability 
[7,64,102–104,115–
118,121,122] 
 
Antibodies (OX-
26, anti-
transferrinR, 83-
14 Mab, anti-
ICAM-1) 
highly 
specific 
limited 
stability 
[6,8,115,119,120,173] 
Peptide 
lipoprotein 
receptor binding 
sequence, 
K16ApoE 
peptide 
greater 
stability  
[174] 
Coating 
(PEG, 
SiO2,Tween-20, 
Tween-80) 
outer coating 
shed ability 
limited 
selectivity 
[64,79,102,128,129] 
Adsorptive-
mediated 
endocytosis 
Peptide 
TAT peptide, 
transportan, 
insulin, FBP, 
MAP, SBP, 
SynB1, SynB3 
greater 
stability 
limited 
selectivity, 
systemic 
toxicity 
[64,82,83,131,132] 
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 Table 2.1 continued 
Physiological 
Hurdle 
Mechanism 
General 
characteristics 
Examples Pros Cons References 
Neuron 
 
Receptor-
mediated 
endocytosis 
Carbohydrate 
FA, Mannose, 
Galactose 
high 
expression, 
stable 
limited 
selectivity 
[175,176] 
Neurotransmitter 
GABA, 
glutamate, 
acetylcholine 
greater 
selectivity 
interference 
with 
signaling 
[145] 
Protein anti-NR1R 
highly 
specific 
limited 
stability 
[147] 
Adsorptive-
mediated 
endocytosis Peptide 
TAT peptide, 
transportan, 
insulin, FBP, 
MAP, SBP, 
SynB1, SynB3 
greater 
stability 
limited 
selectivity, 
systemic 
toxicity 
 
 
 
 
Endosomal 
Escape 
Proton 
sponge effect 
buffering at pH 
7.2-5 
polyethylenimine, 
imidazole 
 
 
 
[149]  
Release of 
ROS 
photosensitizer, 
singlet oxygen 
production 
TPPS4, AlPcS2a, 
dendrimer 
pthalocyanine 
 
 
 
 
[149]  
Pore 
formation 
cationic 
amphiphilic 
peptides 
penton base, 
melittin 
 
 
 
 
[149]  
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 Table 2.1 continued 
Physiological 
Hurdle 
Mechanism 
General 
characteristics 
Examples Pros Cons References 
Organelle Nucleus 
passive NPC 
transport 
< 9 nm  
fewer 
chemical 
modifications 
steric 
limitation 
[159] 
active NPC 
transport 
40-60 nm, NLS  
greater size 
capacity 
steric 
limitation 
[161–163] 
mitotic 
vulnerabilities 
replicating cells  
greater size 
capacity 
exclusive 
to mitotic 
cells 
[164,165] 
shape-
directed 
localization 
biconcave, 
spherical 
morphology 
 
fewer 
chemical 
modifications, 
greater size 
capacity 
platform 
material 
dependence 
[132] 
Mitochondria 
electrostatic 
attraction 
cationic 
amphiphilic 
peptides 
TPP, TAT 
increased 
cytoplasmic 
transport 
toxicity, 
protein 
aggregation 
[3] 
receptor-
mediated 
transport 
mitochondrial 
receptor ligand 
TPSO ligand 
high 
selectivity 
 [153] 
 
3
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3.1 Abstract 
There is an urgent need to deliver anti-oxidant and anti-inflammatory therapeutics 
across the blood-brain barrier (BBB) to treat a variety of brain disorders, including 
neurodegenerative diseases ranging from Parkinson’s Disease to traumatic brain injury and 
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chemical exposure. In this work, using an in vitro BBB model, we demonstrate that a 
biodegradable polyanhydride nanoparticle-based delivery system effectively traverses the 
BBB. Using a combination of confocal microscopy, flow cytometry, and liquid 
chromatography/tandem mass spectroscopy, our data demonstrate the internalization of both 
non-functionalized and folic acid functionalized polyanhydride nanoparticles by primary 
human monocytes and human brain microvascular endothelial cells (HBMEC) and efficient 
transfer of the nanoparticles from monocytes to primary HBMEC in vitro. These nanoparticle 
formulations contained Mito-apocynin, a promising anti-oxidant compound, and the efficient 
transport of this payload into the HBMEC was confirmed using chromatography. The 
versatility of the polyanhydride nanoparticle platform design was exemplified by the ability 
to incorporate targeting ligands via two different functionalization methods, bulk and surface 
functionalization, which can be used for cellular targeting downstream of the BBB. 
Collectively, these studies demonstrate that polyanhydride nanoparticle-based delivery 
systems show promise for enhancing the effectiveness of therapeutics that require transport 
across the BBB and efficient internalization by neuronal cells. 
 
3.2 Introduction 
Age-related neurodegenerative disorders including Alzheimer’s and Parkinson’s 
Disease (AD and PD, respectively), and stroke are becoming more prominent as the world 
population ages [1]. These diseases typically manifest mid- to late-life and progressively 
worsen with increased morbidity. The economic burden associated with increased medical 
management as well as decreased individual productivity is likely to increase in the 
following years, making it increasingly urgent to develop effective medications. Currently, a 
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number of drugs are available in the market that manage the symptoms of AD and PD. 
However these drugs treat only the symptoms and do not slow disease progression.  
In neurodegenerative diseases, one of the major causes of neurodegeneration is 
mitochondrial dysfunction, which leads to a build-up of reactive oxygen and nitrogen species 
(ROS and RNS, respectively), and oxidative stress. While there has been some success in the 
development of anti-inflammatory and antioxidant drugs, the efficacy of those drugs can be 
affected by factors such as drug metabolism, which can reduce its bioavailability and 
appropriate localization, and therefore increase its cytotoxicity and potential side effects. An 
example of such an antioxidant drug that is targeted towards mitochondria is Mito-apocynin 
(mAPO), which was shown in previous studies to reduce oxidative stresses, preserve motor 
coordination, and retain olfactory function in mouse models [2].  
For treatment of central nervous system (CNS) diseases, the major factor that reduces 
drug efficacy is the poor penetration of therapeutics across the blood-brain barrier (BBB) [3]. 
Some classes of polymeric nanoparticles (NPs) have been shown to enhance drug delivery 
across the BBB [4,5]. Polyanhydride particles can provide sustained delivery of a broad 
range of therapeutics [6–16]. Additionally, polyanhydride NPs are biocompatible and 
degrade by surface erosion, which is favorable for therapeutic delivery [17]. Our recent work 
has indicated that mAPO encapsulated in polyanhydride nanoparticles functionalized with 
folic acid were internalized effectively by neuronal cells and provided protection against 
H2O2-induced oxidative stress and 6-OHDA-induced neurodegeneration [18]. However, the 
ability of polyanhydride NPs (with or without folic acid functionalization) to efficiently cross 
the BBB has not yet been investigated.  
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In the present study, we investigated the effects of polyanhydride NP formulations of 
different chemistries on their uptake by primary human brain microvascular endothelial cells 
(HBMEC), the major BBB constituent, as well as by primary human monocytes. The effects 
of monocyte-endothelial cell interactions on NP uptake and cell-to-cell transfer were also 
studied.  
 
3.3 Experimental Methods 
3.3.1 Polyanhydride synthesis 
Synthesis of sebacic anhydride (SA) and 1,6-bis(p-carboxyphenoxy)hexane (CPH) 
pre-polymers and copolymers was performed as previously described [19,20] . The resulting 
20:80 CPH:SA copolymer was characterized using 1H nuclear magnetic resonance 
spectroscopy (1H NMR; VXR-300, Varian, Palo Alto, CA) to verify copolymer composition 
and molecular weight. Appropriate molecular weight of the synthesized copolymers was 
confirmed [19,20]. 
 
3.3.2 Folic acid bulk functionalization 
Bulk functionalization of 20:80 CPH:SA copolymer with folic acid (FA) (bFA-poly) 
was performed using an anhydride interchange mechanism. First, a mass of FA equivalent to 
10 times the molar concentration of copolymer to be reacted was added to a three-pronged 
round bottom flask with 5 mL acetic anhydride and acetylated by refluxing for 60 min at 
150°C under N2. The remaining solution was immediately added to 20:80 CPH:SA 
copolymer, which was reacted at 180°C under 0.5 torr vacuum for 20 min, and dissolved in 
15-20 mL methylene chloride overnight. Undissolved free FA was removed by centrifugation 
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at 10,000 rpm for 5 min. Functionalized, purified polymer was precipitated drop-wise into 
hexanes at a 1:20 methylene chloride:hexanes ratio. The resulting FA-functionalized 
copolymer was characterized using 1H NMR (MR-400, Varian; CDCl3) to estimate the 
percentage of end groups that were functionalized with FA. Additionally, gel permeation 
chromatography (GPC) was used to characterize polymer molecular weight before and after 
functionalization. Finally, Fourier transform infrared spectroscopy (FTIR; Nicolet iS50 
FTIR, ThermoFisher, Waltham, MA) attenuated total reflectance (ATR; Nicolet Smart iTX 
accessory, ThermoFisher; FTIR-ATR) was used to analyze the presence of anhydride peaks 
associated with the polymer before and after functionalization. 
 
3.3.3 Mito-apocynin synthesis 
Mito-apocynin (mAPO) was kindly provided by the Kalyanaraman laboratory at the 
Medical College of Wisconsin. Product synthesis and characterization was performed as 
described previously [2,21,22]. 
 
3.3.4 NP synthesis 
Rhodamine B (Sigma, St. Louis, MO) or mAPO were incorporated into the core of 
20:80 CPH:SA NPs by an anti-solvent nano-encapsulation method [23]. The synthesized 
polymer (100 mg) and rhodamine B (5 mg) or mAPO (0.2 mg) were dispersed into 4-5 mL of 
methylene chloride (Fisher Scientific, Pittsburgh, PA) and sonicated for 30-60s with a probe 
sonicator (Sonics and Materials, Newtown, CT). The solution was poured into 1 L pentane 
(Fisher Scientific) for non-functionalized NP (NF-NP) or 2 L pentane for bulk-FA 
functionalized NPs (bFA-NP), stirring rapidly, and the particles were immediately recovered 
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by vacuum filtration. The particle morphology and size were evaluated with scanning 
electron microscopy (Quanta 250 FE-SEM, FEI, Hillsboro, OR). ImageJ software (National 
Institutes of Health, Bethesda, MD) was used to determine primary particle sizes. 
 
3.3.5 NP surface functionalization 
Surface functionalization of 20:80 CPH:SA NF-NPs with FA was performed using a 
two-step amine-carboxylic acid coupling reaction with 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) and N-hydroxysuccinimide (NHS) [24,25]. The morphology and size of 
the resulting NPs (sFA-NPs) were determined using scanning electron microscopy and 
ImageJ 1.43u software was utilized to determine primary particle sizes. 
 
3.3.6 Human monocyte isolation  
Monocytes were obtained from HIV-1, HIV-2 and hepatitis B seronegative donor 
leukopaks, and separated by countercurrent centrifugal elutriation and characterized as 
previously described [26,27]. Freshly elutriated monocytes were re-suspended in Dulbecco’s 
Modified Eagles Media (DMEM) containing 2 mM L-glutamine (Invitrogen, Carlsbad, CA), 
10% heat-inactivated human serum, 100 g/mL gentamicin, and 10 g/mL ciprofloxacin. All 
reagents were prescreened for endotoxin (<10 pg/mL, Associates of Cape Cod, Woods Hole, 
MA) and mycoplasma contamination (Gen-probe II, Gen-probe, San Diego, CA).  
 
3.3.7 Brain endothelial cell culture 
Primary HBMEC were isolated from brain tissue obtained during surgical removal of 
epileptogenic cerebral cortex in adult patients as we previously described [27–30]. Routine 
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evaluation by immunostaining for von-Willebrand factor, Ulex europaeus lectin and CD31 
(all from Abcam, Cambridge, MA) demonstrated that cells were >99% pure. Freshly isolated 
cells were cultured on collagen-coated culture plates as we previously described [27–29] and 
cells at passage 2 to 4 were used in this study.  
 
3.3.8 Cytotoxicity assays 
Monocytes were cultured at a concentration of 6.25 x 105 cells/mL and HBMEC 
cultured to confluence. For all cell experiments, NPs were suspended in 1 mL of working 
media, and sonicated for 30s. If suspension quality was poor (i.e., if NPs displayed 
aggregation), 0.1% PVA was added as a surfactant. This step was repeated up to 0.4% PVA, 
if necessary. To determine any potential toxic effects of NPs on cells, monocytes and 
confluent HBMEC were treated with NPs at concentrations of 1 to 500 g/mL for 48 h at 
37oC and 5% CO2. Following loading of each NP formulation, cells were washed with 
serum-free culture media to remove excess drugs and cytotoxicity was assessed over 24 h 
using alamarBlueTM assay (Life Technologies) as we previously described [4,31], per 
manufacturer’s instructions. All experiments were performed in triplicate for each 
experimental condition. 
 
3.3.9 Endothelial cell-monocyte NP transfers 
Primary HBMEC were cultured to confluence on glass coverslips as previously 
described [32]. For endothelial cell-monocyte communication, freshly elutriated human 
monocytes were loaded with either 100 or 250 g/mL rhodamine-encapsulated NF-NPs (NF-
NP-rho), bFA-NPs (bFA-NP-rho), or sFA-NPs (sFA-NP-rho) for 48 h. Following NP 
63 
 
loading, monocytes were washed 3 times with PBS to remove any free NPs. Monocytes were 
then co-cultured with endothelial cells for 2 h and HBMEC monolayers were washed 3 to 5 
times with PBS to remove monocytes.  
 
3.3.10 Immunofluorescence and confocal microscopy 
Confluent HBMEC cultured on glass coverslips were fluorescently labeled using the 
Vybrant 1,1 ́dioctadecyl- 3,3,3 ́,3 ́-tetramethylindodicarbocyanine perchlorate (DiO) cell-
labeling solution (excitation 484 nm; emission 501 nm) as we previously described [4]. DiO-
labeled HBMEC were co-cultured for two hours with NF-NP-rho, bFA-NP-rho, or sFA-NP-
rho. Following endothelial cell-monocyte co-culture, HBMEC monolayers were washed 3 to 
5 times with PBS to remove monocytes, mounted in Prolong Gold antifade reagent 
containing DAPI (for nuclear staining) (Life Technologies, Grand Island, NY) and analyzed 
by fluorescence or confocal microscopy as we previously described [4]. To determine the 
localization of NPs in endothelial cells, the triple labeled cell samples were examined under a 
Zeiss LSM 710 confocal laser scanning microscope using Zeiss Zen software.  
 
3.3.11 Fluorescence-activated cell sorting (FACS) 
For FACS quantification of NP uptake by monocytes or HBMEC, the cells were 
exposed to either 100 or 250 g/mL NF-NP-rho, bFA-NP-rho, or sFA-NP-rho for 48 h, and 
washed 3 to 5 times with PBS to remove free NPs. Monocytes and HBMEC were then fixed 
by incubation in 1% paraformaldehyde for 20 min, washed, resuspended in PBS and 
analyzed by FACS, using a FACScan flow cytometer (BD Bioscience, San Jose, CA). The 
mean fluorescence channel – mean number of rhodamine positive cells was derived using 
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CellQuest software (BD Bioscience). To determine the levels of NPs in monocytes and 
HBMEC following monocyte-endothelial cell communication, monocytes loaded with either 
100 or 250 g/mL NF-NP-rho, bFA-NP-rho or sFA-NP-rho were co-cultured for 2 to 4 h 
with HBMEC (unloaded), then washed 3 to 5 times to separate monocytes from endothelial 
cells. HBMEC and monocytes recovered from co-cultures were then fixed by incubation in 
1% paraformaldehyde for 20 min, washed, resuspended in PBS and analyzed by FACS. 
Unloaded monocytes were used for gating when analyzing monocytes samples, while 
unloaded HBMEC were used for gating when analyzing HBMEC from direct loading or co-
cultured experiments. The mean fluorescence channels – mean number of rhodamine positive 
cells was derived using CellQuest software (BD Bioscience). For all FACS analyses, each 
experimental condition was performed in duplicate.   
 
3.3.12 Ultra Performance Liquid Chromatography tandem mass spectrometry (UPLC – 
MS/MS) 
Freshly elutriated human monocytes and HBMEC were loaded with 250 g/mL of 
mAPO-encapsulated NF-NP (NF-NP-mAPO) or sFA-NP (sFA-NP-mAPO) for 48 h as 
described above, were washed 3 to 5 times with PBS to remove free NPs, and harvested and 
pelleted by centrifugation. For monocyte-endothelial cell co-cultures, freshly elutriated 
human monocytes were loaded with 250 g/mL of NF-NP-mAPO and sFA-NP-mAPO for 
48 h, washed 3 to 5 times with PBS to remove free NPs, and co-cultured with HBMEC for 2 
to 4 h. Following co-cultures, monocytes and HBMEC were harvested separately and 
pelleted by centrifugation. Controls consisted of unloaded cells, with and without co-cultures. 
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Controls included untreated HBMEC and HBMEC treated for 2 h with conditioned media 
from NP-free monocytes. HBMEC were then harvested and pelleted by centrifugation.   
For UPLC-MS/MS, each cell pellet was sonicated in 20 L of 0.5 M NaOH, and 
incubated for 30 min at 23oC. Each sample was then mixed with 180 L of methanol, 
centrifuged at 16,000 rcf for 10 min at 4oC; and 70 L transferred to columns and analyzed 
by HPLC (mobile phase: 60% of 0.1% TFA in HPLC H2O, 40% of 0.1% TFA in ACN; flow 
rate: 1.0 mL/min; wavelength for detection: 262 nm). A standard curve of 0 to 6 g/mL of 
mAPO was used for quantitation of NPs in samples.  
 
3.4 Results 
3.4.1 Synthesis and characterization of FA-functionalized polyanhydrides 
A new functionalization method was used to conjugate FA to 20:80 CPH:SA 
copolymer, prior to NP synthesis. End-group functionalization by FA was estimated by 1H 
NMR analysis of purified polymer, by comparing the percentage of non-functionalized 
methyl end-groups (3H, 2.22 ppm) to functionalized FA end-groups using a specific FA-
based aliphatic carbon (2H, 2.05 ppm) (Sup. Fig. 3.3A). This analysis indicated that 
approximately 75% of the end groups were functionalized by FA. GPC analysis of 
functionalized vs. non-functionalized polymer revealed a negligible change in polymer 
molecular weight after bulk functionalization. FTIR-ATR spectroscopy showed a shift in 
anhydride peak composition, reflective of an increase in SA-FA anhydride bonds (Sup. Fig. 
3.3B). 
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3.4.2 Polyanhydride NP synthesis and characterization 
The polyanhydride NPs (with or without FA functionalization) were synthesized by 
flash nanoprecipitation for toxicity, imaging, and BBB transport studies. Different payloads 
(i.e., mAPO or rhodamine B) were successfully incorporated into the NPs, which were 
spherical in shape as anticipated. The characterization data for the NPs used in these studies 
are presented in Table 3.1. All the particle formulations synthesized were approximately 400 
nm in diameter and their surface charge as indicated by zeta potential measurements were 
negative, in agreement with previous studies on NF-NPs and sFA-NPs [18]. No significant 
differences were observed in terms of particle size, morphology and surface charge between 
the NF-NPs, bFA-NPs and sFA-NPs (Table 3.1). 
 
3.4.3 Limited cytotoxicity of polyanhydride NPs in human monocytes and HBMEC  
The toxicity of NF-NPs was evaluated in human monocytes and HBMEC, with each 
experimental condition tested in triplicate. At concentrations of 1 to 100 g/mL, the NF-NPs 
showed limited cytotoxicity in human monocytes, but higher NF-NP concentrations (250 and 
500 g/mL) resulted in increased cytotoxicity and reduced cell viability, compared to 
untreated controls (Fig. 3.1A). Similarly, at concentrations of 1 to 500 g/mL, NF-NPs 
showed limited to no cytotoxicity in HBMEC, but treatment of HBMEC with 500 g/mL of 
NF-NPs resulted in limited cytotoxicity, compared to untreated controls (Fig. 3.1C). The 
toxicity of bFA-NPs and sFA-NPs was also evaluated and these formulations showed low to 
negligible cytotoxicity from 3 to 300 μg/mL (Sup. Fig. 3.1). Based on these studies, NP 
concentrations of 100 or 250 µg/mL were selected for subsequent studies. 
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3.4.4 Monocyte-endothelial cell co-cultures transfer NF-NPs to HBMEC 
HBMEC, the major component of the BBB, is regularly in direct contact with 
circulating blood and separates the systemic circulation from brain tissues. We have 
previously shown uptake of polyanhydride NPs by primary human monocytes [23]. Our 
previous studies also indicated that antigen presenting cells such as dendritic cells and 
macrophages effectively internalize 20:80 CPH:SA nanoparticles, primarily through 
phagocytosis [33,34]. To determine whether circulating monocytes containing NF-NPs can 
transfer the NPs to cells of the brain endothelium, HBMEC were co-cultured with human 
monocytes containing 100 µg/mL or 250 µg/mL NF-NP-rho and the cells were investigated 
using three different methods: confocal microscopy, fluorescence microscopy, and flow 
cytometry.  
Following 2 h of co-culture, transfer of NF-NPs from monocytes to HBMEC 
occurred, and NF-NPs were observed in and around the HBMEC, as shown by confocal 
microscopy (Fig. 3.2).  Furthermore, analyses using XZ or YZ line scan mode of the Zeiss 
LSM 710 confocal imaging program demonstrated localization of NF-NPs at both 250 
µg/mL and 100 µg/mL in the cytoplasm and nucleus of the cells (Fig. 3.2A and 3.2B, 
respectively). Independent validation of NF-NP transfer to HBMEC was performed using 
fluorescence microscopy. Following 2 h of co-culture of HBMEC with NF-NP-loaded 
monocytes, these experiments confirmed that the NPs entered the endothelial cells (Sup. Fig. 
3.2A). Next, FACS was used to quantify the uptake of NF-NPs by monocytes and HBMEC 
and the transfer of NF-NPs through monocyte-endothelial cell communication. Data showed 
efficient uptake of NF-NPs by monocytes (Fig. 3.3A) at 250 g/mL and 100 g/mL (Fig. 
3.3A). Co-culture of NF-NP-loaded monocytes with non-loaded HBMEC was associated 
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with transfer of NF-NPs from monocytes to HBMEC (Fig. 3.3B), and this transfer was 
associated with decreased levels of NF-NPs in the monocytes (Fig. 3.3A). Finally, when the 
particles were directly incubated with the endothelial cells, they were efficiently internalized 
by the endothelial cells (Fig. 3.3C).  
 
3.4.5 UPLC-MS/MS quantification of mAPO in human monocytes and HBMEC 
We used UPLC-MS/MS to quantify mAPO levels in monocytes loaded with 250 
g/mL mAPO encapsulated in NF-NPs, before and after monocyte-endothelial cell co-
cultures. Unloaded monocytes and monocytes loaded with 250 M (or about 125 µg/mL) 
free mAPO were used as controls. The mAPO levels in NF-NP-loaded monocytes were 
approximately two-fold higher than mAPO levels in monocytes, with significantly less 
mAPO loaded in NF-NP-mAPO compared to the free mAPO group (Fig. 3.4A). Co-culture 
of HBMEC with monocytes loaded with mAPO-encapsulated NF-NPs or free mAPO 
decreased mAPO levels in monocytes by 66% and 92%, respectively (Fig. 3.4A).  
Additionally, we used UPLC-MS/MS to quantify mAPO levels in HBMEC directly 
loaded with 250 g/mL of mAPO encapsulated in NF-NPs as well as mAPO levels in 
HBMEC co-cultured with NF-NP-loaded monocytes. Untreated HBMEC and HBMEC 
loaded with 250 M (or about 125 µg/mL) of free mAPO were used as controls. Co-culture 
of HBMEC with monocytes loaded with mAPO encapsulated in NF-NPs resulted in mAPO 
transfer to HBMEC, and higher transfer occurred in co-cultures with NF-NP-loaded 
monocytes compared to co-cultures with monocytes loaded with free mAPO.  While mAPO 
in HBMEC co-cultured with NF-NP-loaded monocytes was detected, no detectable levels of 
mAPO were observed in HBMEC co-cultured with monocytes loaded with free mAPO (Fig. 
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3.4A). The levels of mAPO in NF-NP-loaded HBMEC were more than seven-fold higher 
than mAPO levels in HBMEC loaded with significantly less mAPO loaded in NF-NP-mAPO 
compared to the free mAPO group (Fig. 3.4B).  
 
3.4.6 Internalization of FA-functionalized NPs by HBMEC 
Our previous work has demonstrated that FA-functionalized polyanhydride NPs were 
internalized more effectively by neurons compared to NF-NPs and protected the cells from 
H2O2-induced oxidative stress and 6-OHDA-induced neurodegeneration [18]. To evaluate the 
ability of the FA-functionalized NPs to cross the BBB, we synthesized two types of FA-
functionalized NPs: in the first method, we conjugated FA to 20:80 CPH:SA copolymer and 
prepared NPs based on this conjugated polymer (referred to as bFA-NPs), as described in the 
Methods section. The second method was used to covalently attach FA to 20:80 CPH:SA 
NPs (referred to as sFA-NPs), as described previously [25]. To determine whether circulating 
monocytes containing bFA-NPs and sFA-NPs can also transfer the NPs to cells of the brain 
endothelium, we co-cultured HBMEC with human monocytes containing 100 g/mL bFA-
NP-rho or sFA-NP-rho. Following 2 h of co-culture, transfer of bFA-NP-rho and sFA-NP-
rho from monocytes to HBMEC occurred, and bFA-NP-rho and sFA-NP-rho were observed 
in and around the HBMEC, as indicated by confocal microscopy (Fig. 3.5A). Next, FACS 
was used to quantify the uptake of bFA-NPs and sFA-NPs by monocytes and HBMEC as 
well as the transfer of these NPs through monocyte-endothelial cell communication. Data 
showed uptake of bFA-NP-rho and sFA-NP-rho by monocytes (Fig. 3.5B). To further verify 
whether the sFA-NP-rho transferred to HBMEC entered endothelial cells, we performed 
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fluorescence microscopy. Following 2 h of co-culture of HBMEC with sFA-NP-loaded 
monocytes, the NPs were observed to have entered endothelial cells (Sup. Fig. 3.2B). 
Co-culture of bFA-NP-rho and sFA-NP-rho-loaded monocytes with non-loaded 
HBMEC was associated with transfer of bFA-NP-rho and sFA-NP-rho from monocytes to 
HBMEC (Fig. 3.5B), and this transfer was associated with decreased levels of bFA-NP-rho 
and sFA-NP-rho in the monocytes (Fig. 3.5B). Finally, the FACS analysis also demonstrated 
direct uptake of bFA-NPs and sFA-NPs by endothelial cells (Fig. 3.5C).  
UPLC-MS/MS was used to quantify the amount of mAPO in monocytes incubated 
with 250 g/mL sFA-NP-mAPO. The levels of mAPO in monocytes loaded with sFA-NP-
mAPO were 2.5-fold lower than mAPO levels in monocytes, however with less mAPO in 
sFA-NP-mAPO than in free mAPO (Fig. 3.5D). Co-culture of HBMEC with monocytes 
loaded with sFA-NP-mAPO or free mAPO, decreased mAPO levels in monocytes by 79% 
and 92% respectively (Fig. 3.5D). Additionally, co-culture of HBMEC with monocytes 
loaded with sFA-NP-mAPO resulted in mAPO transfer to HBMEC. While mAPO in 
HBMEC co-cultured with sFA-NP-mAPO-loaded monocytes was detected, no detectable 
levels of mAPO were observed in HBMEC co-cultured with monocytes loaded with free 
mAPO (Fig. 3.5E). 
 
3.5 Discussion 
 There is an urgent need to synthesize delivery platforms that can cross the BBB and 
deliver payloads to neurons and other cells of the CNS to reduce the progression of 
neurodegeneration. Biodegradable polyanhydride nanoparticles represent an attractive 
platform in this regard, based on their high biocompatibility [35–37] and extensive use in 
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drug and vaccine delivery [6–12,14,18,38–43]. Furthermore, carriers based on 
polyanhydrides (i.e., the Gliadel® wafer) have been approved by the U.S. FDA for use in 
humans to treat glioblastoma [44]. However, the ability of polyanhydride NPs 
(functionalized or not) to cross the BBB has not investigated. In our previous work we 
demonstrated that folate-modified polyanhydride nanoparticles were internalized more 
effectively by neurons compared to NF nanoparticles, which resulted in subsequent 
protection against oxidative stress and neurodegeneration [18]. Since polyanhydride particles 
undergo surface erosion, we developed a bulk functionalization technique in which the 
polyanhydride backbone was conjugated with folic acid to improve the likelihood folic acid 
is present on the surface of the polyanhydride nanoparticles once they arrive at their target 
(e.g., neurons). In this work, two methods of transport of both NF and folic acid-
functionalized NPs across the BBB were investigated in vitro: direct particle interaction with 
the HBMEC and monocyte-mediated transport to the HBMEC. 
Polyanhydride NPs have previously been shown to be non-toxic to multiple cell types 
[18,45,46]. In this work we established that polyanhydride NP concentrations at 250 µg/mL 
resulted in limited toxicity to primary human monocytes, as shown in Figure 3.1A, and no 
toxicity to primary HBMEC, as shown in Figure 3.1B. We observed similar biocompatibility 
of the sFA and bFA NP, as indicated in Supplementary Figure 3.1. We have previously 
shown polyanhydride NP compatibility with primary mouse cortical cells up to 
concentrations of 100 µg/mL [18]. The toxicity data obtained in this work provides a wide 
administration window for further studies with polyanhydride NPs for delivery of therapeutic 
cargo across the BBB. Based on these findings, we tested the transfer of 100 and 250 µg/mL 
polyanhydride NPs of different chemistries (NF, sFA, bFA) from monocytes to HBMEC. 
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Previous work with 20:80 CPH:SA NPs demonstrated high levels of particle 
internalization by a human monocyte cell line [23]. This polyanhydride NP backbone 
formulation, 20:80 CPH:SA, has shown superior cellular internalization compared to other 
polyanhydride formulations and does so primarily via phagocytosis [33]. Studies have also 
shown increased macrophage uptake of polyester NPs with the functionalization of folic acid 
[5]. These observations led us to speculate that folic acid modified polyanhydride particles 
would be a prime candidate for use in cell-mediated delivery of encapsulated payloads to the 
brain. However, in these experiments we found that sFA-NP and bFA-NP resulted in similar, 
if not lower, levels of particle uptake by primary human monocytes, as shown in Figure 3.5. 
This suggests that the FA modification may alter the internalization mechanism of the NPs 
from non-specific internalization (i.e., phagocytosis) of the NF polyanhydride NPs to 
receptor-mediated endocytosis of the FA-modified NPs. 
 While we have shown non-specific polyanhydride NP internalization by APCs, we 
have also shown the need for ligands to enhance cellular internalization with other cell types 
[18]. When the polyanhydride NPs were incubated directly with HBMEC, we observed 
enhanced internalization of these particles resulting in dye positive and high drug 
concentrations, as shown in Figures 3.3C and 3.4B, respectively. This suggests that 
polyanhydride NPs are capable of achieving endothelial transcytosis [3]. In work with 
poly(butyl cyanoacrylate) (PCBA) nanoparticles, it was shown that polysorbate surfactant 
and apolipoproteins on the surface of these NPs enhanced BBB transport [47]. In previous 
work, we observed that apolipoproteins were among the serum proteins that adsorbed to the 
surface of polyanhydride NPs upon incubation with serum [48]. This would suggest that 
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polyanhydride NPs with adsorbed serum proteins will also have the potential to interact with 
the BBB and may be capable of crossing the BBB via receptor-mediated transcytosis.  
In this work we have observed similar cellular interactions and transport for the sFA-
NP and bFA-NP, as shown in Figure 3.5. This suggests that the amount of FA on the surface 
of the bFA-NP is maintained for longer periods of time during the degradation process. 
Although the sFA-NP were less effectively internalized by monocytes than the NF-NP, we 
still observed quantifiable drug transport from the monocyte-loaded cells to the HBMEC, as 
shown in Figure 3.5D,E. Based on this work, it is clear that bFA-functionalized, sFA-
functionalized, and NF polyanhydride NPs can be transported across the BBB via cell-
mediated methods.  
In previous studies, mAPO treated transgenic mice showed less motor coordination 
loss [2]. The current studies show that encapsulation of mAPO in polyanhydride NPs can 
increase the availability of the mAPO at the BBB interface by both direct NP- and cell-
mediated interactions with the HBMEC, as shown in Figure 3.4. Other recent work from our 
laboratories showed enhanced protection of primary mouse neuronal cells with folate 
modified mAPO-loaded polyanhydride NPs [18]. Therefore, the bFA-NP represents the most 
promising formulation for the delivery of mAPO to neuronal cells. Collectively, these studies 
demonstrate that polyanhydride NP-based delivery systems show promise for enhancing the 
effectiveness of therapeutics that require transport across the BBB and for their enhanced 
delivery to neurons. 
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3.6 Conclusions 
 This work expands the literature on the excellent biocompatibility of polyanhydride 
NPs with different types of cellular systems. We have shown the internalization of both NF 
and folic acid functionalized NPs by primary human monocytes and efficient transfer of the 
NPs by the monocytes to primary HBMEC in vitro. There is also evidence that the NF 
polyanhydride NPs could be internalized directly by primary HBMEC in vitro. Based on this 
work, polyanhydride NPs show promise as a drug delivery vehicle to enhance the 
effectiveness of therapeutics that require transport across the BBB. 
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3.10 Tables and Figures 
Table 3.1. Particle Characteristics. Scale bar on images is 500 nm. 
Surface Loading SEM 
photomicrographs 
Geometric 
Diameter 
(nm) 
Zeta 
Potential 
(mV) 
Unmodified 
20:80 
CPH:SA (NP) 
RhoB 
 
410 ± 21 -21.5 ± 
0.7 
Unmodified 
20:80 
CPH:SA (NP) 
mAPO 
 
398 -19 ± 0.5 
sFA-modified 
20:80 
CPH:SA 
(sFA-NP) 
RhoB 
 
457 ± 74 -12.0 ± 
1.4 
sFA-modified 
20:80 
CPH:SA 
(sFA-NP) 
mAPO 
 
425 N/A 
bFA-modified 
20:80 
CPH:SA 
(bFA-NP) 
RhoB 
 
414 ± 39 -21.9 ± 
0.6 
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Figure 3.1: Effect of NF-NP concentration on the viability of human monocytes (A), human 
MDM (B), and HBMEC (C). Cells from human donors were isolated and cultured as 
described in the Methods, loaded with NPs at different concentrations (1 μg/mL, 10 μg/mL, 
100 μg/mL, 250 μg/mL and 500 μg/mL) for 48 h and toxicity was assessed over 24 h using 
the alamarBlueTM assay. *p<0.05, **p<0.01, ∞p<0.001, #p<0.0001, compared to untreated 
controls. 
 
77 
 
 
Figure 3.2. NF-NP-rho are efficiently internalized by HBMEC following co-culture with 
NF-NP-rho-loaded monocytes. Monocytes loaded with NF-NP-rho were co-cultured with 
HBMEC labeled with DiO (green), and NF-NP-rho uptake following endothelial-monocyte 
communication was visualized by confocal microscopy. Representative images showing 
uptake of NF-NP-rho at 250 µg/mL (A) and 100 µg/mL (B) by primary HBMEC. 
 
 
Figure 3.3: FACS quantification of direct uptake of NF-NP-rho by primary human 
monocytes (A), cell-to-cell transfer of NPs following co-culture of HBMEC with NF-NP-
rho-loaded monocytes (B), and direct uptake by HBMEC. “Before cc”: NPs levels in cells 
before monocytes-endothelial co-culture. “After cc”: NPs levels in cells after monocytes-
endothelial co-culture. Experiments were performed with both 250 µg/mL and 100 µg/mL 
NF-NP-rho. Data represents mean ± SEM of three replicates (**p<0.01, ***p<0.001). 
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Figure 3.4: HPLC quantification of NF-NP-mAPO and free-mAPO direct uptake by primary 
human monocytes, cell-to-cell transfer of NPs following co-culture of HBMEC with NP-
loaded monocytes (A), and direct uptake by HBMEC (B). “Before cc”: NPs levels in cells 
before monocytes-endothelial co-culture. “After cc”: NPs levels in cells after monocytes-
endothelial co-culture. Experiments were performed with 250 µg/mL NF-NP-mAPO, and 
with 250 µM free mAPO. Data represents mean ± SEM of three replicates (*p<0.05, 
**p<0.01, ***p<0.001). 
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Figure 3.5: Quantification of sFA-NP and bFA-NP uptake in HBMEC and monocytes. (A) 
Representative confocal microscopy images showing sFA-NP-rho and bFA-NP-rho uptake 
by HBMEC after co-culture with monocytes. (B) Monocytes were loaded with 100 µg/mL 
sFA-NP-rho or bFA-NP-rho, and co-cultured with HBMEC. FACS quantification of sFA-
NP-rho and bFA-NP-rho in primary human monocytes before co-culture and monocytes and 
HBMEC after co-culture. (C) FACS quantification showing direct uptake of sFA-NP-rho and 
bFA-NP-rho NPs in HBMEC. (D) HBMEC were co-cultured with monocytes loaded with 
250 µg/mL sFA-NP-mAPO or 250 µM free mAPO. mAPO levels in monocytes before and 
after co-culture, and in HBMEC after co-culture were quantified by HPLC at 262 nm. (E) 
HPLC quantification of direct uptake of sFA-NP-mAPO and free mAPO in HBMEC. 
*p<0.05, ***p<0.001. 
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Supplementary Figure 3.1: Effects of sFA-NP and bFA-NP on the viability of human 
monocytes (A & B), human MDM (C & D), and HBMEC (E & F). Cells from human donors 
were isolated and cultured as described in the Methods, incubated with NPs of different 
concentrations (3 μg/mL, 10 μg/mL, 30 μg/mL, 100 μg/mL and 300 μg/mL) for 48 h and 
toxicity was assessed over 24 h by the alamarBlueTM assay. 
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Supplementary Figure 3.2: Representative immunofluorescence images showing 
endothelial uptake of NF-NP-rho (A, B) and sFA-NP-rho (C, D) following co-culture with 
monocytes. Primary human monocytes loaded with NF-NP-rho or sFA-NP-rho were co-
cultured with HBMEC labeled with DiO (Green), washed and NP uptake analyzed by 
immunofluorescence and confocal microscopy.  
(A) 
 
bFA-poly 
NF-poly 
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(B) 
 
Supplementary Figure 3.3. Characterization of bFA- vs. non-functionalized 20:80 
CPH:SA copolymer. (A) 1H NMR of bFA- vs non-functionalized 20:80 CPH:SA 
copolymer. Appearance of an FA-based aliphatic carbons (δ=2.05 (2H, m), 2.39 (2H, t)) in 
FA-polymer indicates functionalization. Percent functionalization was estimated by end-
group analysis of purified polymer, by back-calculating the molar ratio of FA to 20:80 
CPH:SA. (B) FTIR-ATR spectroscopy of FA- vs. non-functionalized 20:80 CPH:SA 
copolymer, after purification. Red arrows indicate the decrease in the relative peak height of 
methyl end-groups (2870 cm-1) and SA-SA anhydride bonds (1740 cm-1). Blue arrows at 
1460 cm-1 and 1610 cm-1 indicate the appearance of new peaks representing FA in the 
copolymer. 
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4.1 Abstract 
Neurodegeneration due to chemical exposure and/or conditions such as Parkinson’s 
disease and traumatic brain injury leads to significant deleterious events that affect the 
performance of neurons. Even with survival after acute exposure, affected neurons 
experience oxidative stress. Treatment of oxidative stress using antioxidants is essential for 
preventing irreversible damage to the central nervous system. Targeting specific ligands to 
nano-carriers that encapsulate anti-oxidant drugs is a valuable approach to overcome the 
complex hurdles associated with central nervous system delivery that block efficient drug 
bioavailability and lead to protection of cells by lowering the oxidative stress. In this context, 
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polyanhydride nanoparticles containing anti-oxidants have shown the ability to improve drug 
delivery to neurons. This work expands upon the design of the polyanhydride nanoparticle 
platform by using a novel functionalization method to conjugate polyanhydrides with a 
blood-brain barrier and mitochondrial targeting ligand, triphenylphosphonium (TPP), prior to 
nanoparticle synthesis. Enhanced internalization of the TPP functionalized nanoparticles by 
neurons was demonstrated using flow cytometry and supported by confocal microscopy. 
Finally, improvements in the efficacy of a mitochondrially-targeted antioxidant, Mito-
apocynin, for protection against oxidative stress were observed when treating the cells with 
Mito-Apo containing functionalized nano-carriers, while also providing dose-sparing effects. 
These studies lay the platform for therapeutic delivery to the brain and set the stage for in 
vivo studies in the appropriate disease models. 
 
4.2 Introduction 
Exposure to toxic organophosphates affects as many as three million individuals each 
year, with as many as 10% of these exposures resulting in death [1]. In order to prevent the 
development of chronic symptoms and progression of neurodegeneration, rapid treatment in 
the hours to days after exposure is essential. Antioxidants are a class of drugs used to treat 
mitochondrial oxidative stress that often follows chemical exposure in this timescale and is 
also present in many chronic neurodegenerative conditions [2].  
Apocynin is an antioxidant that has been used in several studies for treatment of 
oxidative stress in pre-clinical Parkinson’s disease models [3–5]. The dimer diapocynin has 
also shown protection against oxidative stress in mouse models [6,7]. In order to improve 
drug targeting to mitochondria, a lipophilic cation, triphenylphosphonium (TPP), has been 
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conjugated to apocynin (Mito-Apo) [6,8,9]. An eleven carbon chain derivative of Mito-Apo 
(Mito-Apo C11) has shown protection in MitoPark and LRRK2R1441G transgenic mouse 
models [6,8], while a two carbon chain derivative (Mito-Apo C2) has shown protection in a 
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (MPTP) model [9]. To further improve drug 
efficacy of Mito-Apo, nano-carriers can be used to encapsulate and provide sustained release 
of the drug. 
Nano-carriers can improve drug bioavailability and efficacy for central nervous 
system (CNS) delivery by achieving passage across complex physiological hurdles while 
protecting the drug from degradation [10]. Furthermore, targeting ligands can be conjugated 
to antioxidant-encapsulated biodegradable nanomaterials to improve the ability to cross the 
blood-brain barrier (BBB), be internalized by diseased neurons, and co-localize with the 
mitochondria [10,11]. In this regard, biodegradable polyanhydride nanoparticles (NPs) 
represent an attractive nanoscale drug delivery platform technology, and have demonstrated 
sustained release of therapeutics to counter a broad range of diseases [11–25]. The Gliadel® 
wafer, an FDA-approved polyanhydride-based drug delivery product for delivery of the drug 
carmustine to treat cancer, is an excellent example of CNS drug delivery [26]. 
The clinical applicability of polyanhydrides is attributed to their high biocompatibility 
[27]. In addition, polyanhydrides are relatively hydrophobic polymers, and therefore tend to 
degrade by surface erosion [28,29]. This feature is particularly advantageous compared to 
bulk eroding drug release platforms, because it allows for predictable drug release rate that 
can be altered by simply changing the copolymer composition [27,30,31]. By enabling 
sustained and local release of drug to diseased neurons and protecting it from systemic 
degradation, polyanhydride NPs have shown superior dose-sparing effects [17,32]. 
92 
 
Neuronal delivery of antioxidants encapsulated within NPs based on 1,6-bis-(p-
carboxyphenoxy)hexane and sebacic acid (i.e., 20:80 CPH:SA) significantly improved 
protection against oxidative stress [11]. In addition to the improved efficacy and targeting to 
neurons, 20:80 CPH:SA NPs are internalized effectively by phagocytic cells [33], can rapidly 
deliver payloads for combating oxidative stress [34,35], and efficiently encapsulate the 
therapeutic Mito-Apo [36]. This makes 20:80 CPH:SA NPs an excellent candidate for CNS 
drug delivery. 
Efficacy and localization of nanoscale delivery platforms can be further improved 
through functionalization with targeting ligands [37–39]. For example, folic acid (FA) has 
improved neuronal targeting of 20:80 CPH:SA NPs [11]. However, this functionalization did 
not improve transport across the BBB compared to the non-functionalized counterpart, as 
demonstrated in Chapter 3. It is necessary to design a delivery platform that can effectively 
surmount multiple complex hurdles associated with CNS drug delivery, including crossing 
the BBB and enhancing neuronal targeting and uptake. The targeting ligand, 
triphenylphosphonium (TPP), has shown the ability to improve BBB transport and enable 
mitochondrial targeting of delivery platforms [40–43], and additionally improve drug 
efficacy by direct conjugation [6,8,9], making it an excellent choice of targeting ligand to 
further optimize the 20:80 CPH:SA NP-based nanomedicine platform. 
Many targeting ligands used for drug delivery are conjugated on the surface of the 
nanoscale delivery platform [11]; this may cause a loss of the ligand by degradation before 
achieving its targeting goal when administered in vivo. To enable prolonged persistence of a 
ligand such as TPP to more effectively improve CNS delivery, this work investigated the use 
of a novel functionalization method that conjugates the targeting ligand to the polymer prior 
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to NP synthesis. The molecule (3-carboxypropyl)triphenylphosphonium (CPTP, a derivative 
of TPP) was used to synthesize functionalized 20:80 CPH:SA NPs (CPTP-NPs), which 
contained quantum dots (QDs; QD:(CPTP-NP)s) and the internalization of these NPs by N27 
cells, a rat mesencephalic neuronal cell line, was compared to that of non-functionalized 
20:80 CPH:SA NPs containing QDs (or QD:NPs). The efficacy of CPTP-NPs against 
hydrogen peroxide (H2O2)-induced oxidative stress was tested after encapsulating Mito-Apo 
C2 (or simply Mito-Apo) into both NPs and CPTP-NPs (represented by M:NPs and 
M:(CPTP-NP)s, respectively). 
 
4.3 Experimental Methods 
4.3.1 Materials 
20:80 CPH:SA copolymer synthesis was performed as described previously [34,44]. 
1H nuclear magnetic resonance (NMR; MR-400, Varian) was used to measure the polymer 
molecular weight and purity. MTS cell viability dye (Catalog # G3580) was purchased from 
Promega. Caspase-3 substrate (Catalog # 556449) was purchased from BD Biosciences. 
MitoTracker® Red and Hoechst 34580 were purchased from ThermoFisher Scientific. 
HEPES, 3-[(3-Cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS), 
2,2',2'',2'''-(Ethane-1,2-diyldinitrilo)tetraacetic acid (EDTA), dithiothreitol (DTT) and sucrose 
were purchased from Sigma (St. Louis, MO). Dulbecco’s modified Eagle’s medium 
(DMEM), Roswell Park Memorial Institute medium (RPMI) 1640, fetal bovine serum (FBS), 
trypsin/EDTA (TE), L-glutamine, penicillin, and streptomycin were purchased from 
Invitrogen (Carlsbad, CA). Mito-Apo was kindly provided by the Kalyanaraman laboratory 
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at the Medical College of Wisconsin. Synthesis and characterization of the final product were 
performed as described previously [11]. 
 
4.3.2 Synthesis of CdSe-ZnS core-shell nanoparticles 
Cadmium selenide NPs were synthesized following a standard air-free hot-injection 
reaction procedure modified from Pu et al. [45] and ZnS shell growth was achieved using a 
procedure modified from Talapin et al. [46]. Cadmium oxide (0.25 mmol, 32 mg) was 
dissolved in 2 mL of 1-octadecene (ODE) and 218 µL oleic acid (OA) in a 4 mL glass vial. A 
0.4 M stock solution of selenium in ODE was prepared by sonicating 384 mg of selenium in 
12.190 mL ODE using bath sonication. A Zn:S precursor solution was prepared by 
dissolving zinc chloride (0.19 mmol, 26 mg) and 51.43 µL of bis(trimethyldisilyl) sulfide in 
1.436 mL of trioctylphosphine (TOP). To synthesize CdSe NPs, the solution of CdO in ODE 
and OA was heated to 240°C on an aluminum reaction block under nitrogen atmosphere. 310 
µL of Se in ODE was injected into the reaction vial and the vial was removed from heat. To 
synthesize CdSe-ZnS core-shell NPs, the crude solution of CdSe as prepared above was 
cooled slightly to 220°C and the aforementioned Zn:S precursor solution was added 
dropwise to the CdSe solution under vigorous stirring. The resultant nanoparticles were 
washed once with methanol and twice with ethanol before being dispersed in methylene 
chloride.  
 
4.3.3 Polyanhydride bulk functionalization 
An excess of CPTP was acetylated under N2 in approximately 5 mL acetic anhydride 
for 60 min at 150 °C. Excess acetic anhydride was removed using a rotary evaporator. The 
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remaining solution was immediately pipetted into 20:80 CPH:SA copolymer. Conjugation of 
CPTP to copolymer by an anhydride interchange mechanism was performed by reacting 
under vacuum at 0.5 torr for 20 min at 180 °C. The conjugated copolymer was dissolved in 
methylene chloride (Fisher Scientific, Pittsburgh, PA) overnight. Functionalized copolymer 
was precipitated into hexanes at a methylene chloride:hexanes volume ratio of 1:25 and 
filtered. 
After polymer precipitation, excess free CPTP was purified from the copolymer by 
sonicating in nanopure water for 30 s, centrifuging at 10,000 rpm for 5 min, and removing 
the supernatant. Percentage end-group functionalization of copolymer was characterized 
using 1H NMR (MR-400 MHz, Varian, Palo Alto, CA; CHCl3-d1) end-group analysis. 
Specifically, percent functionalization was estimated by back-calculating the molar ratio of 
CPTP to 20:80 CPH:SA using the area under characteristic peaks from each material. Fourier 
transform infrared (FTIR; Nicolet iS50 FTIR, ThermoFisher, Waltham, MA) attenuated total 
reflectance (ATR; Nicolet Smart iTX accessory, ThermoFisher; FTIR-ATR) spectroscopy 
was also used to characterize structural changes after functionalization. Confirmation of 
polymer molecular weight after functionalization was evaluated using gel permeation 
chromatography (GPC; Optilab® T-rEX, Wyatt, Santa Barbara, CA). The same 
functionalization procedure was used for FA-functionalized polymer, except purification was 
with methylene chloride, retaining the polymer in the solution and disposing un-dissolved 
free FA. 
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4.3.4 Nanoparticle synthesis and characterization 
Either QD or Mito-Apo was encapsulated into 20:80 CPH:SA NPs by a modified 
anti-solvent nano-encapsulation method [47]. Briefly, the synthesized polymer (100 mg) and 
QD (5 mg) or Mito-Apo (0.2 mg) were dispersed into 5 mL of methylene chloride and 
sonicated for 60 s with a probe sonicator (Sonics and Materials, Newtown, CT). The solution 
was poured into 1 L of pentane (Fisher Scientific) and the particles were recovered by 
vacuum filtration. The particle morphology and size were determined using scanning electron 
microscopy (SEM; Quanta 250 FE-SEM, FEI, Hillsboro, OR). ImageJ software (National 
Institutes of Health, Bethesda, MD) was used to quantify particle size distribution. Solvents 
and glassware used to prepare NPs were sterile.  
To evaluate drug release kinetics, NPs with or without Mito-Apo were suspended at 
10 mg/mL in 1x phosphate-buffered saline (PBS), and sonicated for 30 s. Samples were then 
incubated in a 37 °C rotator. At respective time points, supernatant from samples was 
collected via centrifugation. Samples were replaced with fresh PBS to maintain perfect sink 
conditions. The supernatant was analyzed for drug concentration using high-performance 
liquid chromatography (HPLC, Agilent Technologies 1200, Santa Clara, CA).  
To evaluate surface charge, NPs and CPTP-NPs were weighed at approximately 1 mg 
and brought to 1 mg/mL in nanopure water. The suspension was sonicated for 30 s and 
diluted to 0.1 mg/mL in nanopure water, and sonicated for 30 s. The zeta potential 
measurement was recorded immediately using a ZetaSizer (Zetasizer Nano, Malvern 
Instruments Ltd., Malvern, UK). 
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4.3.5 N27 cell culture and cytotoxicity testing 
A rat mesencephalic neuronal cell line (N27) was used for cytotoxicity, efficacy and 
localization experiments. Cells were thawed from liquid nitrogen, and immediately added to 
RPMI media (RPMI 1640, B27 supplement, 10% fetal bovine serum (FBS), L-glutamine, 
penicillin, and streptomycin). Cells were centrifuged for 5 min at 1,000 rpm, aspirating 
supernatant. 15 mL RPMI was added to suspend cells, which were plated onto a T75 flask, 
replacing media the next day. Upon reaching 70% confluence, N27 cells were passaged by 
trypsinization using trypsin/EDTA. Cells were mixed and counted using a Vi-Cell XR 
instrument (Beckman Coulter, Brea, CA). For seeding a T75 flask, one million cells were 
added. To plate into 96, 24, or 6-well plates, cells were plated at approximately 5,000 
cells/well, 20,000 cells/well, or 200,000 cells/well, respectively. After 24 h, media was 
aspirated and the appropriate treatment was added to cells in 2% FBS-containing RPMI (2% 
RPMI). 
To test NP and CPTP-NP cytotoxicity, cells were grown to 70% confluence in 96-
well plates in 10% RPMI. NP stock suspensions were sonicated in 2% RPMI for 60 s using a 
bath sonicator. Old media on cells was aspirated and replaced by 2% RPMI containing NPs 
or CPTP-NPs. At 24 h, 10 μL MTS dye was added to each well. 96 well plates were read 1 h 
after adding the dye using a spectrophotometer (SpectraMax 190, Molecular Devices, 
Sunnyvale, California; 490nm). The experiments were performed in triplicate. 
 
4.3.6 Fluorescence-activated cell sorting 
Cells were grown to 70% confluence in 6 well plates with 10% RPMI. Stock 
suspensions of 5% QD:NPs and QD:(CPTP-NP)s were sonicated in 2% RPMI for ~60s using 
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a bath sonicator. Old media was aspirated from 6-well plates and cells were treated with 30 
μg/mL of either QD:NPs or QD:(CPTP-NP)s. After 20 h, media was aspirated and wells 
were washed with PBS. Cells were collected using a cell scraper, transferred to individual 1.5 
mL microcentrifuge tubes and centrifuged at 1,000 rpm for 7 min. PBS was aspirated and 
replaced with 4% paraformaldehyde (PFA). Each tube was mixed thoroughly by pipetting to 
ensure fixation. Cells were stored in 4 °C in the dark. Immediately before analysis, the cells 
were centrifuged and PFA was replaced with 1% bovine serum albumin (BSA) in PBS, and 
processed via flow cytometry using a 488 nm laser (FACSCanto, BD Biosciences, San Jose, 
CA). The experiments were performed in triplicate. 
 
4.3.7 Confocal microscopy 
Cells were grown to 70% confluence in 24-well plates on Poly D-Lysine-coated glass 
coverslips in 10% RPMI. NP stock suspensions were sonicated in 2% RPMI for ~60 s using 
a bath sonicator. Cells were treated with 30 μg/mL QD:NPs or QD:(CPTP-NP)s in 2% RPMI 
for 24 h. Then, media was aspirated and cells were washed in pre-warmed (37 °C) HEPES 
buffered saline solution (HBSS). Next, HBSS was aspirated and the cells were incubated 
with HBSS containing 1/7,000 MitoTracker® Red, and 1/5,000 Hoechst dyes for 8 min. 
HBSS was aspirated and the cells were then washed two times with room temperature PBS 
and fixed with room temperature 4% PFA. The coverslips were mounted onto SuperFrost® 
Slides (Sigma) for confocal microscopy (Leica SP5 X MP confocal/multiphoton 
microscope). The experiments were performed in triplicate. 
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4.3.8 Cell viability by MTS assay 
Cells were grown to 70% confluence in 96-well plates in 10% RPMI. NP stock 
suspensions were sonicated in 2% RPMI for ~60 s using a bath sonicator. Old media on the 
cells was aspirated and replaced by 2% RPMI containing 30 μg/mL NPs or 10 μM soluble 
Mito-Apo C2. At 18 h, cells were challenged with 100 μM H2O2 (+/- challenge control). 
After a 6 h H2O2 challenge, 10 μL MTS dye was added to each well. 96-well plates were read 
1.5 h after adding the dye using a 96-well plate reader. The experiments were performed in 
triplicate. 
 
4.3.9 Cleaved caspase-3 quantification 
Cells were grown to 70% confluence in 6-well plates in 10% RPMI. NP stock 
suspensions were sonicated in 2% RPMI for ~60 s using a bath sonicator. Old media was 
aspirated and cells were treated with either soluble 10 μM Mito-Apo C2 or 30 μg/mL Mito-
Apo C2-encapsulated NPs. At 18 h, cells were challenged with 100 μM H2O2 (+/- challenge 
control). After 6 h H2O2 challenge, supernatant from each well was centrifuged in individual 
microcentrifuge tubes at 1,000 rpm for 5 min to collect floating cells. Adherent cells were 
detached by aspirating media and adding 0.5 mL TE for 2 min. TE was neutralized by adding 
1.0 mL 2% RPMI, and cells were centrifuged at 1,000 rpm for 5 min in corresponding tubes. 
Supernatant was aspirated and cells were rinsed with ice-cold PBS, followed by 
centrifugation at 1,000 rpm for 5 min. Supernatant was aspirated and 250 μL caspase buffer 
(50 mM HEPES, 10% sucrose, 0.1% CHAPS, 1 mM EDTA, 10 mM DTT) was added to 
each sample, vortexing to lyse cells. Samples were incubated at 37 °C for 20 min on a 
shaker. Samples were centrifuged at 13,200 rpm for 5 min before transferring 190 μL 
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supernatant from each sample to a 96 well plate. To each sample, 10 μL caspase-3 substrate 
was added. After incubating at 37 °C for one hour on a shaker, the fluorescence was 
quantified using a 96-well plate reader (ex: 380 nm, em: 460 nm). A NP only control was 
used for both NP and CPTP-NP remove fluorescent signal associated with NPs. The 
experiments were performed in triplicate. 
 
4.3.10 Statistical analysis 
Graphical data were statistically analyzed using a one or two-way ANOVA for 
multiple comparisons, or a student’s t-test for individual comparisons, on GraphPad Prism® 
software. Comparisons were marked for significance at p-values less than 0.05, 0.01 or 
0.001. 
 
4.4 Results 
4.4.1 Characterization of functionalized polymer 
Previous studies demonstrate that 20:80 CPH:SA molecular weights between 10-15 
kDa were suitable for synthesizing NPs [47]. Molecular weights for the polymer used in this 
study were confirmed to be in this range by 1H NMR. After bulk functionalization with 
CPTP, a small change in copolymer molecular weight was observed using GPC. 
Functionalization of CPTP was indicated by 1H NMR analysis, which showed the 
existence of phenyl group peaks representing CPTP after purification (δ 7.73-7.83 (15H, m), 
Figure 4.1 A). Simultaneously, a decrease in the non-functionalized methyl end-group (δ 
2.22 (3H, s)) was observed. The percent conjugation was determined by calculating the peak 
area ratio of CPTP to 20:80 CPH:SA copolymer peaks in a purified solution, and then back-
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calculating the molar ratio (with two moles of possible end-groups available for 
functionalization on each copolymer chain), leading to an estimated 45% functionalization of 
the polymer used in this study. 
Previous analysis of 20:80 CPH:SA copolymer by FTIR-ATR showed peaks from 
1700-1800 cm-1 indicative of SA-SA anhydride bonds [48]; further, peaks were present at 
2900 cm-1 indicative of methyl end-groups from the non-functionalized polymer. After 
functionalization with CPTP followed by polymer purification, a shift in the composition of 
anhydride bonds was observed in the 1700-1800 cm-1 range indicating a change in the 
proportion of anhydride bonds. Additionally, a decrease in the intensity of methyl group 
peaks was observed, indicating a change in the proportion of functional end-groups of the 
polymer (Fig. 4.1 B). Furthermore, new peaks were observed in the spectrum of the 
functionalized polymer at 1440 cm-1 and 1720 cm-1 representative of the targeting ligand, 
CPTP. Taken together, all of these methods demonstrated CPTP functionalization of the 
20:80 CPH:SA copolymer. 
 
4.4.2 Characterization of nanoparticles and drug release kinetics 
Table 4.1 lists the morphology, size, and zeta potential of the formulations 
synthesized for this study. All NP formulations were spherical and the sizes were within 
range of previously reported values, which demonstrated optimal cellular internalization [47]. 
Additionally, a release study with 5 wt% M:NPs showed a drug encapsulation efficiency of 
20%, with about one third of the drug being released from the NPs within the first day of 
incubation in PBS (Fig. 4.2). Studies with 0.2 wt% M:NPs and 0.2 wt% M:(CPTP-NP)s are 
currently underway to characterize release kinetics of the NP formulations used in this study. 
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4.4.3 Cytotoxicity and internalization in N27 cells 
NPs and CPTP-NPs were evaluated for potential cytotoxicity in the N27 cells. Up to a 
concentration of 30 μg/mL, neither formulation showed any detrimental effects on cell 
viability (Fig. 4.3). Next, differences in internalization capability of QD:NPs and QD:(CPTP-
NP)s in N27 neurons were evaluated using flow cytometry and confocal microscopy. The 
flow cytometric data indicated that QD:(CPTP-NP)s were internalized more efficiently than 
QD:NPs, with 37% of cells internalizing QD:(CPTP-NP)s and only 19% of cells 
internalizing QD:NPs (Fig. 4.4). Additionally, confocal microscopy of cells incubated with 
QD:NPs and QD:(CPTP-NP)s for 24 h confirmed neuronal internalization of both 
formulations (Fig. 4.5). 
 
4.4.4 Protection against H2O2 challenge in N27 cells 
The viability of N27 cells incubated with M:NPs or M:(CPTP-NP)s after H2O2 
challenge was evaluated to observe whether there were improvements in drug efficacy 
elicited by M:(CPTP-NP)s. It was found that after a 6 h H2O2 challenge, 0.2 wt% M:(CPTP-
NP)s improved protection against oxidative stress over 0.2 wt% M:NPs by an MTS assay 
(Fig. 4.6). Additionally, a caspase-3 assay was performed on cells treated with 0.2 wt% 
M:NPs and 0.2 wt% M:(CPTP-NP)s 18 h prior to a 6 h H2O2 challenge to further evaluate 
enhancement of protection elicited by M:(CPTP-NP)s. It was found that both M:NPs and 
M:(CPTP-NP)s sufficiently protected against H2O2 – induced toxicity after a 6 hour 
challenge (Fig. 4.7). This further emphasizes the dose-sparing properties of the M:(CPTP-
NP)s as observed in the MTS assay. 
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4.5 Discussion 
There is an urgent need to develop more effective therapeutic options for treatment of 
chemical exposure. Mito-Apo has demonstrated efficacy in protecting against oxidative 
stress both in vitro and in vivo [6,8,9,11]. However, some potential improvements that can be 
attained include sustained drug release to increase the bioavailability, and lowering the 
therapeutic dose to avoid systemic toxicity. In this work, we used a rat mesencephalic 
neuronal cell line to demonstrate that nano-carriers based on CPTP-functionalized 
polyanhydrides were internalized more effectively by the cells and protected the cells from 
H2O2 challenge in comparison with their non-functionalized nano-carrier counterparts. 
An important characteristic of CNS delivery platforms is the ability to target the 
complex hurdles impeding efficient drug protection. The development of a bulk 
functionalization method enables the conjugation of the targeting ligand to the polymer prior 
NP synthesis; after NP synthesis, CPTP will exist throughout the bulk of the NP, rather than 
just on the surface as is the case when NPs are functionalized with ligands [11].  Therefore, 
as the NP degrades, the CPTP will persist as part of the NPs, enabling prolonged targeting 
capability. This is particularly advantageous over surface functionalization methods of NPs, 
in which the targeting ligand is released immediately upon onset of degradation. 
The structural characteristics of the NPs were relatively unchanged after 
functionalization and no detrimental effects of the targeting ligand were observed during NP 
synthesis. Size and morphology of CPTP-NPs, with or without Mito-Apo or QDs, was 
unchanged after functionalization (Table 4.1). Additionally, studies comparing the release 
profiles of 5 wt% M:NPs and FA-functionalized 5 wt% M:NPs (M:(FA-NP)s) showed no 
change in drug EE of M:(FA-NP)s compared to M:NPs (Fig. 4.2), indicating that the bulk 
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functionalization method does not negatively impact the EE of Mito-Apo within 20:80 
CPH:SA NPs. It is expected that the 0.2 wt% M:NPs and 0.2 wt% M:(CPTP-NP)s used in 
this study will have a larger EE due to a smaller diffusion gradient forcing the drug out of the 
polymer matrix during NP synthesis, compared to 5 wt% M:NPs. Additionally, it is expected 
that 0.2 wt% M:(CPTP-NP)s will have a similar EE to 0.2 wt% M:NPs. Studies are currently 
underway to assess these hypotheses. 
The mitochondrial-targeting properties of TPP make it an excellent choice for 
improving delivery of antioxidants [6,41,49–62]. Incorporation of this cationic targeting 
ligand into NPs did not affect the biocompatibility of the NPs in N27 cells (Fig. 4.3), and a 
non-toxic concentration of 30 µg/mL NPs was therefore used in all the subsequent 
localization and efficacy studies. By incorporating TPP within this NP formulation, it was 
expected that cellular internalization via adsorptive-mediated endocytosis would be further 
enhanced. Flow cytometry was performed to evaluate this hypothesis. The CPTP-
functionalized formulation demonstrated enhanced cellular internalization compared to the 
NPs (Fig. 4.4). This enhanced targeting may be due to a higher affinity of the more positively 
charged CPTP-NPs for the negative neuronal membrane and therefore enhance adsorptive-
mediated endocytosis by non-specific electrostatic interaction [58,63]. It is also known that 
20:80 CPH:SA NPs may be internalized by non-specific, non-adsorptive mechanisms as well 
[33] (Chapter 3). 
Confocal microscopy was used to corroborate the internalization behavior observed 
with the flow cytometric analysis. After 24 h, both NPs and CPTP-NPs were localized 
around the cells (Fig. 4.5 A and B, respectively). This suggests that both NPs and CPTP-NPs 
are able to achieve rapid cellular entry in order to quickly deliver drug for immediate 
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protection against oxidative stress, as shown in the efficacy studies (Figs. 4.6 and 4.7) and 
supported by the burst release profile observed in the first few hours after incubation (Fig. 
4.2). This suggests that incorporating a cationic ligand with the negatively charged 20:80 
CPH:SA NPs may improve the affinity of the CPTP-NPs for the negatively charged 
mitochondrial membrane [64,65]. 
In addition to testing for enhanced neuronal internalization and mitochondrial co-
localization, the ability to enhance drug efficacy is important for therapeutic delivery 
platforms. The toxin H2O2 is widely used to test the efficacy of antioxidants, because it leads 
to the formation of dangerous superoxide radicals in the cell [11]. Therefore, H2O2 was used 
in this study to evaluate the ability of the NP formulations to enhance the protective 
capability of Mito-Apo in N27 cells. An added benefit of NPs is the ability to provide 
sustained release to protect the cells for a longer period of time than would administration of 
a large bolus of drug. After encapsulating Mito-Apo in both NPs and FA-NPs, functionalized 
in the same way as CPTP-NPs, the rate of drug release was observed to be zero-order over 
the first few days of release (Fig 4.2). This constant release rate may lead to increased local 
bioavailability around the site of the diseased neurons. The enhanced protection over soluble 
drug after the 6 h challenge by an MTS cell viability assay (Fig. 4.6) indicates that the 
sustained release properties enabled by these NP formulations increased the local 
bioavailability of the drug and helped lower oxidative stress over several hours. These in 
vitro results are promising initial steps towards translating these studies into animal models. 
To further evaluate the ability of CPTP-NPs to improve protection, a caspase-3 assay 
was performed to evaluate the amount of cell death [11,66–68]. After quantifying the amount 
of caspase-3 signal following H2O2 challenge, both NP formulations protected against 
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oxidative stress (Fig. 4.7). The EE of these 0.2% Mito-Apo-loaded NP formulations is 
expected to be of the order of 50-60% (studies are underway to measure the EE), indicating 
significantly less drug used compared to the soluble dose group. This observation 
demonstrates the dose-sparing properties of the bulk-functionalized polyanhydride NPs, in 
agreement with previous observations with surface-functionalized formulations [11]. 
 
4.6 Conclusions 
Using a NP platform based on biodegradable polyanhydrides for cellular 
internalization and sustained release of therapeutics, a novel bulk functionalization method 
was used to conjugate a derivative of TPP to 20:80 CPH:SA copolymer before NP synthesis. 
CPTP-NPs showed enhanced cellular internalization over NPs in a rat mesencephalic 
neuronal cell line. Additionally, Mito-Apo containing functionalized NP formulations 
showed enhanced efficacy in protecting the cells against H2O2, with a significantly lower 
therapeutic drug concentration than administering the drug solubly. Furthermore, bulk-
functionalizing TPP to 20:80 CPH:SA NPs may enhance neuronal membrane targeting and 
improve co-localization with the mitochondria in vivo. Therefore, it is a promising candidate 
for treatment of oxidative stress buildup in the brain. 
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4.10 Tables and Figures 
Table 4.1. Particle Characteristics. n=3 for size quantification and zeta potential 
measurements. Scale bar on images is 3 μm. 
NP 
Formulation 
Loading 
SEM 
photomicrographs 
Geometric 
Diameter 
(nm) 
Zeta 
Potential 
(mV) 
NP 
None 
 
295 ± 99 -18.3 
0.2% 
Mito-Apo 
 
306 ± 99 -15.9 
5% QD 
 
232 ± 68 -19.5 
 CPTP-NP 
None 
 
368 ± 109 -7.6 
0.2% 
Mito-Apo 
 
371 ± 105 -3.8 
5% QD 
 
314 ± 96 5.1 
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Figure 4.1. Characterization of CPTP- vs. non-functionalized 20:80 CPH:SA 
copolymer. (A) 1H NMR of CPTP- vs non-functionalized 20:80 CPH:SA copolymer. 
Appearance of the phenyl group (δ=7.73-7.83 (15H, m)) and decrease in the methyl 
functional group (δ=2.22 (3H, s)) in CPTP-polymer indicates functionalization. Percent 
functionalization was estimated by end-group analysis of purified polymer, by back-
calculating the molar ratio of CPTP to 20:80 CPH:SA. (B) FTIR-ATR spectroscopy of 
CPTP- vs non-functionalized 20:80 CPH:SA copolymer, after purification. Red arrows 
indicate the decrease in the relative peak height of methyl end-groups (2870 cm-1) and SA-
SA anhydride bonds (1740 cm-1). Blue arrows at 1440 cm-1 and 1720 cm-1 indicate the 
appearance of new peaks representing CPTP in the copolymer.
(A) 
(B) 
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Figure 4.2. Mito-Apo release kinetics of 5%-loaded NPs. The concentration of Mito-Apo 
released over time in M:NPs and M:(FA-NP)s was measured using HPLC (Agilent 
Technologies 1200) and the amount of Mito-Apo released at each time point was normalized 
by the total amount of Mito-Apo released (20% drug EE for both NP formulations). Error 
bars represent standard error of the mean (n=3). 
 
 
Figure 4.3. Biocompatibility of NPs and CPTP-NPs in N27 cells. NPs and CPTP-NPs at 
different concentrations as indicated were incubated with N27 cells in 2% RPMI for 24 h 
before adding 10 μL MTS dye to each well. Absorbance was measured after 1 h in MTS dye 
using a 96-well plate reader. Error bars represent the standard error of the mean (n=8). 
111 
 
 
Figure 4.4. Cellular internalization of QD:NPs and QD:(CPTP-NP)s by flow cytometric 
analysis. N27 cells were incubated with QD:NPs) or CPTP-NPs for 20 h in 2% RPMI. The 
6-well plates were then washed with PBS and cells were collected using a cell scraper. After 
centrifuging 1,000 rpm for 7 minutes, cells were fixed with PFA. Prior to analysis, cells were 
re-suspended in a 1% BSA buffer in glass test tubes. Fluorescence was measured using a 488 
nm laser, and cells were separated from debris based on morphology. Error bars represent the 
standard error of the mean (n=3). 
 
                
Figure 4.5. Cellular internalization of QD:NPs and QD:(CPTP-NP)s. Confocal 
microscopy of QD:NPs (A) and QD:(CPTP-NP)s (B) (green) incubated with cells for 24 h 
before staining for mitochondria (red) and nucleus (blue) and fixing. Internalization is 
confirmed by the existence of nanoparticles in plane with the cells both from a top-down 
view and in the cross section. Mitochondrial co-localization is represented by a yellow 
signal. Scale bar on images is 10 µm. Inset scale bar: 5 µm. 
(A) (B) 
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Figure 4.6. Protection against H2O2 – induced cell death in N27 neurons. After 
incubating cells for 18 h with either 30 µg/mL M:NPs, M:(CPTP-NP)s or soluble Mito-Apo 
(including +/- toxin challenge control), media was replaced with 2% RPMI containing 100 
μM H2O2 as well as the same concentration of M:NPs, M:(CPTP-NP)s or soluble Mito-Apo 
and cells were challenged for 6 h. After 6 h challenge, 10 µL MTS dye was added and 
absorbance was measured after 1.5 h of incubation with MTS dye at 490 nm using a 96 well 
plate reader. Error bars represent standard error of the mean (n=3). 
 
Figure 4.7. Protection against H2O2 – induced cell death in N27 neurons by cleaved 
caspase-3 quantification. After incubating cells for 18 h with either 30 µg/mL M:NPs, 
M:(CPTP-NP)s or 10 µM Mito-Apo (including +/- toxin challenge control), media was 
replaced with 2% RPMI containing 100 μM H2O2 as well as the same concentration of 
M:NPs, M:(CPTP-NP)s or soluble Mito-Apo for 6 h. After 6 h challenge, cells were 
collected using TE. Cells were lysed using a Caspase-3 buffer, and then supernatant from 
lysate was incubated with Caspase-3 substrate for 1 h before measuring fluorescence (em: 
380, ex: 460 nm) using a 96 well plate reader. Error bars represent standard error of the mean 
(n=3). 
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CHAPTER 5: CONCLUSIONS AND ONGOING/FUTURE WORK 
5.1 Conclusions 
Rapid treatment of oxidative stress using antioxidants is necessary to combat 
neurodegeneration due to chemical exposure and other causes. Drug-encapsulating nanoscale 
delivery platforms with conjugated targeting moieties can significantly improve drug efficacy for 
treatment of oxidative stress. The 20 mol% 1,6-bis(p-carboxyphenoxy)hexane (CPH), 80 mol% 
sebacic acid (SA; 20:80 CPH:SA) polyanhydride nanoparticle (NP) platform has demonstrated 
sustained release, dose-sparing and cellular internalization properties that make it promising for 
central nervous system (CNS) drug delivery [1–3].  
To effectively treat oxidative stress, a delivery platform should be able to effectively 
cross the blood-brain barrier (BBB), enable delivery to diseased neuron, and co-localize to the 
mitochondria (Chapter 2). To understand the BBB crossing capability of these NPs, 
internalization in both BBB endothelial cells and monocytes was evaluated using non-, surface-, 
and bulk-functionalized formulations using the targeting ligand, folic acid. The 20:80 CPH:SA 
NPs showed internalization by both the endothelial cells and the monocytes in this model; 
however, the targeting ligands did not improve internalization (Chapter 3). Then, to further test 
this platform, (3-carboxypropyl)triphenylphosphonium (CPTP) bulk-functionalized 20:80 
CPH:SA NPs (CPTP-NPs) were synthesized and evaluated for the ability to be internalized by 
neurons, co-localize to the mitochondria, and overall improve the protection against oxidative 
stress after encapsulating the antioxidant Mito-apocynin. These CPTP-NPs were proven to be 
effective on all of these measures (Chapter 4). Further optimization of this platform is necessary 
to fully take advantage of the capability of this promising platform. 
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5.2 Ongoing and Future Work 
To further optimize 20:80 CPH:SA NPs, they can be functionalized on the surface and in 
bulk simultaneously, with two different targeting ligands [2] (Chapters 3 and 4). A cascading, 
multiscale NP platform with bulk-conjugated moieties for targeting the neuron and mitochondria, 
and surface-conjugated moieties for targeting the BBB could significantly improve CNS delivery 
of therapeutics. This optimized platform would be tested using BBB and neuronal models, as 
described below. In vivo studies are then necessary to evaluate whether the developed NP 
platform can show this multiscale, cascading property and improve drug pharmacokinetics and 
pharmacodynamics for treatment of neurodegenerative disease. 
 
5.2.1 In vitro polyanhydride NP formulation optimization 
 To optimize this polyanhydride NP platform, an optimal BBB-targeting ligand is needed. 
One strategy could involve conjugating chemokines to the surface of the NPs. These proteins can 
stimulate a pathway in the brain that ultimately enhances the immune response, which in doing 
so leads to more immune cell recruitment into the brain [4]. As discussed, 20:80 CPH:SA NPs 
additionally show superior uptake, and subsequent release, by immune cells [3] (Chapter 3). 
Therefore, surface functionalizing these NPs with a chemokine could lead to enhanced local NP 
concentration near the site of inflammation in the brain. Alternatively, surfactants have 
demonstrated the ability to inhibit efflux pumps on BBB endothelial cells, and additionally 
increase cell membrane fluidity, and therefore could also be incorporated into the NP platform to 
improve brain localization [5]. After enhanced brain localization provided by the surface-
conjugated moiety, bulk-functionalization of NPs with a proven neuronal and mitochondrial 
targeting moiety such as CPTP could further enhance drug efficacy. Ultimately, platform 
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optimization using BBB and neuronal in vitro models would reveal a lead candidate for in vivo 
testing. 
 
5.2.2 In vivo biodistribution studies 
Internalization of NPs by BBB endothelial cells in vivo would prove significantly more 
challenging than for an in vitro BBB model. This necessitates an in vivo biodistribution study for 
the lead NP candidate. Brain bioavailability could be assessed at several different time points to 
generate a pharmacokinetic profile. Additionally, as mentioned in Chapter 2, the route of 
delivery plays an important role in vivo. Therefore, the choice between intranasal and 
intravenous delivery routes must be made for this study. Finally, as pathogenesis can play a role 
in BBB permeability, the study should test localization in both diseased and healthy mice. 
 
5.2.3 In vivo protection studies 
An in vivo protection study would evaluate whether the lead candidate can significantly 
improve drug pharmacodynamics. Parkinson’s disease-based neurodegenerative models such as 
the MitoPark model and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model could 
be considered for this study [6,7]. Alternatively, protection against irreversible neuronal damage 
after chemical exposure could also be evaluated with this platform in vivo by challenging mice 
with a toxic agent and evaluating protection afterwards using several behavioral characterization 
measures [8]. Overall, the optimization of this cascading, multiscale platform could significantly 
improve drug efficacy for neurodegenerative disease treatment, and would be evaluated by this 
study. 
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